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IV The history of the polycystic ovary syndrome 
 
 
 “Giovane rustica, maritata, 
modicamente pingue, et infeconda, con 
due ovaie più grandi del normale, come 
uova di colomba, bernoccolute, lucenti et 
biancastre…“ (Young peasant woman, 
married, moderately lump and infertile, 
with ovaries larger than normal, like 
doves´ eggs, lumpy, shiny and 
whitish…)  This description from 1721 
by the Italian scientist Antonio Vallisneri 
is probably the first text of polycystic 
ovary syndrome (PCOS) 1.  
 
 
Antonio Vallisneri (1661-1730) Italian 
physician, biologist, botanist, geologist 
veterinarian, linguist and hydrologist. 
 
In 1844 Chereau described sclerotic changes in the ovary 2. The association between 
hyperandrogenism and diabetes was first described by Achard and Thiers in 1921, in the 
paper “Le virilism pilaire et son association á l´insuffisance glycolytique” 3. 
In 1935, the two American gynecologists, Stein and Leventhal published a classic 
paper on a series of seven patients 4. They described bilaterally enlarged polycystic 
ovaries, “two to four times the normal size, sometimes distinctly globular”, “tunica 
thickened, though, and fibrotic”, “follicle cysts near the cortex and almost entirely 
confined to the cortex”. “The colour of the ovary was oyster gray with bluish areas where 
the cysts were superficial and appeared on the surface as sago-like bodies”. Other 
characteristics included oligo-amenorrhea, hirsutism and infertility.  
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 According to Stein and Leventhal the diagnosis was based on the clinical appearance: 
hirsuitism, amenorrhea, infertility and histological specimen of polycystic ovaries with 
prominent theca, fibrotic 
thickening of the tunica 
albuginea and multiple cystic 
follicles 4.  
In the 1960s it became 
evident that the “Stein-Leventhal 
syndrome” represented a variety 
of clinical manifestations. In the 
early 1970s, the scientific 
community focused on the 
changed function in the 
hypothalamic – pituitary – 
ovarian axis, increased serum 
levels of LH, and elevated 
LH/FSH ratio 5.  
In the late 1970s the concept of PCOS developed. Burghen et al. were first to point 
out a link between PCOS and insulin resistance. They demonstrated that 
hyperandrogenism correlate with hyperinsulinemia in obese PCOS women 6. This was an 
important milestone.  
Later, ultrasound became central in visualizing polycystic ovaries (PCO) and 
diagnosing PCOS. Swanson et al. were the first to describe the typical ultrasonographic 
appearance of polycystic ovaries in 1981 7, and Adams et al. refined the criteria for the 
ultrasonographic diagnosis of PCO 8 . 
The first treatment for PCOS was bilateral wedge resection of the ovaries, 
suggested by Stein and Leventhal. They reported regain of regular menstruations in seven 
patients, and pregnancy in two women, after wedge resection. Half a century later 
Gjønnæss, a Norwegian gynecologist, introduced laparoscopic ovarian drilling, as a more 
conservative method with fewer problems with adhesions 9. 
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V Polycystic ovaries 
 
a) Definition 
PCO reflects a description of ovarian morphology, from histological visualization or 
ultrasound imaging. The first definition suggested by Adams et al. was 10 or more 
follicles arranged peripherally 8.  
The definition for PCO was revised in 2003 10. Balen and co-workers suggested: 
1. 12 or more follicles in each ovary, each follicle measuring 2-9 mm in diameter 
and/or 
2. Ovarian volume >10ml 
Stromal density and distribution of the follicles are not included in the revised definition 
of PCO. Transabdominal and transvaginal ultrasound examination methods correlate well, 
and both are acceptable tools for the diagnosis 11. The criteria for polycystic ovaries are 
not applicable for adolescent girls 12, women using contraceptive pills 13, and 
postmenopausal women 14. In menstruating women, examination should be performed on 
the third to the fifth day of the menstrual cycle 10. 
Ultrasound image of a polycystic ovary.  
 Photo: Vidar v. Düring 
 
b) Prevalence 
 The prevalence of PCO in the general population is 
reported to be between 17-22 % when ovaries are 
assessed by transabdominal ultrasound 11,15-17.  
With transvaginal ultrasound the prevalence of PCO 
is reported slightly higher (21-28 %) 11,18.  
Younger women seem to have PCO more often than those above 35 years of age 18. 
 
 
VI Polycystic ovary syndrome 
 
a) Definition 
Until 2003 there was no international consensus on the definition of PCOS. In the United 
States, the National Institute of Health (NIH) Conference on PCOS 1990 recommended 
that diagnostic criteria should include evidence of hyperandrogenism (clinical or 
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 biochemical) and ovulatory dysfunction in the absence of non-classic congenital adrenal 
hyperplasia (CAH). Polycystic ovarian morphology was not considered essential. A clear 
definition of ovulatory dysfunction, hirsutism or hyperandrogenism was, however, not 
given 19. PCOS according to this definition was recognized in three principal phenotypes: 
1) women with hirsutism, hyperandrogenemia and oligo-ovulation,  
2) women with hirsutism and oligo-ovulation and  
3) women with hyperandrogenemia and oligo-ovulation. 
In Europe, the definition of PCOS was restricted to a condition with polycystic 
ovaries, identified by ultrasonography and one or more of the following; 
oligoamenorrhea, hyperandrogenism, obesity, elevated serum testosterone and / or 
elevated LH concentrations 19. Ovulatory dysfunction was not mandatory 20,21.  
The need for a universal agreement on the definition of PCOS was obvious.  In 
Rotterdam in 2003, the European Society of Human Reproduction and Embryology 
(ESHRE) and the American Society of Reproductive Medicine (ASRM) achieved a new 
consensus 22. The new definition reflects the awareness that PCOS represents a multitude 
of clinical expressions and emphasizes the importance of realising it.  
According to the Rotterdam 2003 consensus, two of the following three criteria must be 
fulfilled for the diagnosis: 
1. Polycystic ovaries; 12 or more follicles in each ovary, each follicle measuring 
2-9 mm in diameter and/or ovarian volume >10ml. One polycystic ovary is 
sufficient for the diagnosis 
2. Oligo-/anovulation; clinically diagnosed as oligo-/ amenorrhea, i.e. menstrual 
cycles longer than 35 days or less than 10 menstruations per year 
3. Hyperandrogenism; clinical or biochemical 
The clinical definition of hyperandrogenism includes: hirsutism, acne and androgen 
alopecia, but the evaluation of hirsutism is difficult, because of racial differences 23,24. 
Cosmetic treatment abolishes the expression and although there exists standardised 
scoring, the Ferrimann-Gallwey score is seldom used 25. The Rotterdam consensus on the 
definition of PCOS has not defined clinical hyperandrogenism. The definition of 
biochemical hyperandrogenism is not without problems;  
1. Modern immunoassay methods in routine clinical practice have recently been 
shown to be inaccurate for measuring testosterone in women 26. 
2. Normative ranges are not established, and adjustment for age and BMI should be 
recommended.  
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 3. Other androgens than testosterone should also be considered, especially DHEAS 
and androstenedione. 
The diagnosis of PCOS should not be based on one single criterion, and it can be argued 
that PCOS is a diagnosis of exclusions. Congenital adrenal hyperplasia, non-classic 
congenital adrenal hyperplasia, Cushing syndrome, acromegaly and androgen secreting 
tumours should be ruled out. 
It is important to realise that the Rotterdam criteria has expanded the definition of 
PCOS compared with the NIH criteria, and created two new phenotypes i.e. 1) women 
with PCO, hirsutism / hyperandrogenemia and regular ovulations and 2) women with 
PCO, oligo-ovulations and normal androgens 27. 
 
b) Prevalence 
Although PCOS occurs universally, the prevalence, the time of onset of the clinical 
symptoms, and the severity of clinical presentations differ between ethnic and racial 
groups 18,28-31. It is also possible that the occurrence of PCOS varies with time within a 
population, due to the association with insulin resistance and circulating insulin levels 
(see below). 
The reported prevalence of PCOS varies from 3 % to 11 % depending on 
diagnostic criteria used and the population studied 29,32-35. Prevalence studies according to 
the Rotterdam criteria are not yet available. Probably, the prevalence will be higher 
because the Rotterdam criteria have a wider definition of PCOS than the previously used 
definitions.  
 
 
VII Pathogenesis 
 
PCOS is a common, but complex disorder. Its etiology is poorly understood, and different 
hypotheses have been proposed. There is some evidence for a genetic predisposition 36,37. 
Environmental factors seem to play an important role in the clinical presentation of the 
disorder. 
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 a) Genetic predisposition 
There is a reported familial clustering of PCOS, which may suggest a genetic component 
of the disorder 38-41. Hyperandrogenism is one of the important inheritable characteristics 
42. Confounding environmental factors, limited number of family members due to sub-
fertility, heterogeneous phenotypes, and lack of a uniform definition of PCOS have made 
genetic studies difficult.  
 Insulin resistance and early male pattern baldness in men seems to be a male 
phenotype of PCOS 43. There is evidence for an autosomal dominant genetic model with 
low penetrance 44. Genes involved in the regulation of steroid hormone synthesis and 
androgen receptor modulation have been suggested as an explanation for the genetic basis 
of PCOS 45,46. These genes are CYP17A gene which encodes for the P450c 17α enzyme, 
and CYP11A gene encoding for the P450 side-chain cleavage enzyme47. The insulin gene, 
variable number tandem repeat (VNTR) has also been associated with the disturbances of 
the carbohydrate metabolism in PCOS 46. More than one gene seems to be involved. 
Hence, polygenic inheritance seems to be responsible in the majority of cases. Results are, 
however, not conclusive and larger studies are needed 48. 
 In one study, Hispanic American, Japanese, and Italian women with PCOS were 
investigated 49. They had similar androgen levels, insulin resistance and prevalence of 
polycystic ovaries, but the Japanese PCOS women were less hirsute and less obese than 
the others. This demonstrates that clinical expression might differ according to genetic 
differences in ethnic populations. 
 
b) Prenatal factors 
One hypothesis for the pathogenesis of PCOS, is that the developmental process in utero 
or in early postnatal life is influenced by genetic and environmental factors 50,51.  
Female rhesus monkeys exposed prenatally to increased levels of testosterone, 
(their mothers were treated with testosterone during pregnancy), exhibit abnormal LH 
secretion, abnormal insulin secretion, central obesity and hyper-androgenic anovulation as 
adult animals, and their menarche was delayed by six months 52. Similar observations 
have been made in sheep 53. In both species, the ovaries were enlarged with multiple 
antral follicles. The clinical picture was equivalent to PCOS in humans. 
Androgens are potent gene transcription factors. They can interact with their own 
receptors and potentiate gene expression through serine phosphorylation of cAMP 54. 
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 Hence, there is a possibility that androgen excess in human fetuses results in imprinting, 
which later in life can result in the PCOS phenotype.  
Ewes exposed to testosterone during pregnancy gave birth to small newborn lambs 
55. This supports the concept that fetal growth restriction and postnatal catch-up growth, 
can be programmed by prenatal exposure to sex steroids. 
Other hypotheses suggest that a hyper-androgenic fetal ovary 56 or a hyper-
androgenic adrenal cortex  57 are sources for prenatal androgen excess.  Androgen 
exposure in utero may diminish hormonal negative feedback on the hypothalamic-pituary 
axis leading to increased LH amplitude and frequency. LH is an important stimulator of 
ovarian steroid hormone synthesis, and this may result in increased stimulation of 
androgen production and secretion from the ovaries later in life. The ovarian response to 
HCG and GnRH is exaggerated in women with PCOS. Both in vitro and in vivo studies 
have shown increased androgen production from the theca cells in PCOS women 58,59.  
 
c) Environmental factors 
Diet and physical activity have major influence on the severity and expression of PCOS. 
Calorie restrictions, leading to at least 5% weight loss, resulted in increased insulin 
sensitivity, decreased circulating insulin levels and ovulation 60,61.   
A diet rich in carbohydrates and monosaturated fatty acids may adversely 
influence the metabolic manifestation of the syndrome. In Great Britain PCOS women 
from the Indian subcontinent have more pronounced insulin resistance, hirsutism, acne, 
and sub-fertility than Caucasian counterparts with similar BMI. Clinical and biochemical 
presentations seem to be influenced by diet and lifestyle factors 31. 
 
d) Insulin resistance  
It is reported on association between obesity, insulin resistance and impaired fertility in 
PCOS women 60,62,63. Although insulin resistance is not a criterion for the PCOS 
diagnosis, it is a central feature of the syndrome.  
The definition of insulin resistance is based on the effect of insulin on glucose 
homeostasis. Insulin resistance may be defined as increased insulin demand to maintain 
blood glucose levels normal. Among the most frequently used methods to measure insulin 
resistance in large scale studies are: fasting insulin, insulin c-peptide, insulin levels during 
an oral glucose tolerance test (OGTT), and homeostasis assessment model (HOMA) and 
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 hyperinsulinemic clamp. More sophisticated methods also exist, but they are not feasible 
in routine clinical use or large scale studies. 
Anovulatory PCOS women are more insulin resistant and, thus, hyperinsulinemic 
compared to weight matched women with normal ovulations. Insulin resistance seems to 
be selective for fibroblasts, muscle cells and adipose tissue in PCOS 64.  
Insulin stimulates androgen synthesis in both the ovaries and adrenals 65,66. 
Ovarian stroma, theca cells and the adrenals are not resistant to the effect of insulin on 
androgen synthesis. Further, insulin acts synergistically with LH and augments steroid 
synthesis in the ovaries, resulting in follicle arrest and anovulation 67. 
Insulin also inhibits the synthesis of sex hormone binding globulin (SHBG) in the 
liver, resulting in higher levels of free testosterone 68. 
Rhesus monkeys exposed to androgens in utero show impairment of insulin 
secretion and insulin action 69. Abott et al. hypothesized that hyperandrogenemia during 
fetal development has an effect on body fat distribution, leading to centralized fat 
distribution, which in turn predisposes to insulin resistance 50.  
The timing of fetal exposure to hyperandrogenism seems important, as maternal 
injection of testosterone in the early gestation leads to impaired beta-cell function and 
diminished ability of pancreatic beta-cells to respond to hyperglycemic episodes. 
Testosterone exposure in late gestation seems to result in increased visceral adiposity and 
increased insulin resistance in monkeys 50. 
 
e) Anthropologic reflections 
Until recently it may have been advantageous for a woman to be hyper-androgenic. With 
increased physical strength she had increased working capacity, in hunter, gatherer and 
agricultural societies, and, hence a better chance for survival. Probably, she could also 
better defend herself and her offspring. Further, insulin resistance enhanced her ability to 
store energy as subcutaneous fat when food was abundant. This helped her through 
periods of starvation. Food was limited in most societies and the physical demands of 
everyday life so hard, that she did not develop a full-blown PCOS. Hence, her fertility 
would not be significantly reduced. 
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VIII Clinical presentations of PCOS 
 
a) Menstrual disturbances 
Menstrual disturbances are common among PCOS women. The typical pattern is 
infrequent menstruations and occasional spottings, frequently seen as a result of 
anovulation.  The three largest studies estimate that 80-90 % of the PCOS women have 
oligo-amenorrhea 19,70,71. Neither of these studies was based on the Rotterdam 2003 
criteria. 
A regular menstrual pattern is influenced by weight loss and weight gain, and obesity 
augments anovulation 72. 
 
b) Obesity 
The prevalence of obesity varies largely among PCOS women, depending on the 
population studied and the diagnostic criteria used. It is estimated that up to half of the 
PCOS patients are overweight (BMI > 25 kg/m2) or obese (BMI > 30 kg/m2) 61,73. 
PCOS women usually have the so called “male pattern obesity” or “central 
obesity”, which is associated with insulin resistance, increased risk of cardiovascular 
disease and type 2 diabetes 74,75.  
It is a clinical experience that PCOS women date their debut of symptoms to a 
period of increase in body weight, which often coincidence with a time of decreased 
physical activity.  
 
c) Hirsutism 
The prevalence of hirsutism varies with the population studied. Hirsutism in women is 
male pattern of body hair growth and is a clinical sign of hyperandrogenemia. Androgens 
stimulate hair follicles to thicker and darker hair growth. 
Typically, hirsutism is seen as excess facial hair and /or hair on the chest and 
lower abdomen. The Ferriman-Gallwey score can be used to objectively classify hirsutism 
25. In PCOS women, the incidence of hirsutism is as high as 65-70 % 19,70,71.  The 
prevalence and extent of hirsutism depend on the ethnicity of the group studied. Hirsutism 
in Japanese women with PCOS is less common 49.  
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 d) Androgenic alopecia 
Androgenic alopecia is a male type of hair loss from the terminal hair of the scalp. From 
clinical experience, we believe that alopecia is under-diagnosed in Scandinavian women 
with PCOS. Balen and Franks estimated the prevalence of alopecia to 6% and 3 %, 
respectively, in PCOS women 19,70. Interestingly, one study reported that of 89 women 
with androgenic alopecia, 67% had polycystic ovaries 76.  
 
e) Acantosis nigricans 
Acantosis nigricans manifests as skin pigmentation and papillomatosis. It is associated 
with insulin resistance and increased insulin secretion. It has been suggested that the skin 
lesion is due to increased insulin stimulated melanin synthesis in the melanocytes of the 
dermis. Acantosis nigricans is typically seen in areas with increased mechanical exposure, 
such as the neck, the armpits and the groin. It has been reported to be present in 3 % of 
women with PCOS and is more frequent in dark-skinned populations. 19.  
 
 
IX PCO, PCOS and early pregnancy complications  
 
Infertility and sub-fertility is one of the main reasons for PCOS women to consult the 
health service. Increased risk for pregnancy complications has, however, not been 
acknowledged by clinicians, and this problem has not been a major topic in textbooks of 
obstetrics and gynecology. 
The notion that PCOS patients had increased risk for early pregnancy loss (EPL) 
became evident by studies carried out on patients with recurrent pregnancy loss (RPL) 
and IVF treatment.  
 
a) PCO and early pregnancy loss 
In a pioneer work from 1988, Sagle and colleagues reported that 82% of 56 spontaneously 
ovulating women with recurrent pregnancy loss (RPL) had polycystic ovaries (PCO) 
compared to 18% among parous controls 77. Later, four prospective studies confirmed a 
high prevalence of PCO (36-81 %) in women with RPL 78-81. Sub-fertility and obesity are 
increased among women with RPL 78,80. A retrospective study on 1060 IVF treated 
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 women demonstrated that those with PCO had 36% spontaneous abortions compared to 
24% among those with normal ovaries 82 (Table 1).  
However, one prospective study on lean, regularly menstruating women suffering 
from RPL, found that PCO did not predict poor pregnancy outcome 81 (Table 1). Probably 
this can be explained by that, only a few women in this group of lean patients with regular 
menstruations and PCO had PCOS. 
 
b) PCOS and early pregnancy loss 
Homburg found, in a prospective study, that 11 of 27 PCOS women who became 
pregnant after pulsatile LH releasing hormone treatment experienced EPL. Two 
retrospective studies reported 42% and 62% EPL in PCOS women 83,84 (Table 2). 
Clinically recognized EPL in a general population in Norway was estimated to be about 
8-9% 85. A prospective study on healthy women found 16 % EPL 86. 
There is increasing evidence that women diagnosed with PCOS have an increased 
risk for EPL. There seems to be a 2-4 fold increased risk, depending on the population 
studied and diagnostic criteria used.   
 The pathogenesis for early pregnancy loss in PCOS women is unknown. 
Hypersecretion of LH, hyperandrogenism and insulin resistance has been suggested as 
possible etiological factors. 
 
1)  Hypersecretion of LH 
Elevated or disturbed LH secretion during the follicular phase may play a negative role 
for pregnancy outcome. Homburg et al. reported that PCOS women with EPL had high 
concentrations of LH during the follicular phase compared with PCOS women who 
continued the pregnancy 87. High pre-pregnant LH levels predicted increased risk for early 
pregnancy loss in women suffering from RPL. Sixty five percent of the women who had 
LH levels above 10 IU/L in pre-pregnancy follicular phase experienced EPL 88. In a 
prospective study among women with RPL, 81% had abnormalities in the LH secretion 80.  
Study results are, however, somewhat diverging dependent on the LH measurement 
methods and the populations studied. Rai et al. reported that in spontaneously conceiving, 
normal weight women with RPL, LH or testosterone levels were not associated with the 
miscarriage rate 89. Serial measurements or urinary samples are necessary, because of the 
pulsatile nature of LH secretion (Table 3). 
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 Suggested mechanisms of action for abnormal LH secretion are premature oocyte 
maturation, follicle atresia and an androgen-dominated milieu in the endometrium.  
Abnormal LH secretion in the follicular phase seems to have a negative impact on 
early pregnancy outcome. 
 
2) Hyperandrogenism 
Obesity and the accompanying insulin resistance will increase hyperandrogenemia in 
PCOS, by inhibiting the hepatic synthesis of sex hormone binding globulin (SHBG). 
Tulppala reported that women with RPL with a new miscarriage in the index pregnancy 
had higher free testosterone and DHEAS levels than those who completed the pregnancy 
79. Women with RPL have higher testosterone levels than normal fertile controls 80,90. 
Androgens may act as antagonists to estrogens in the endometrium. Okon et al. postulated 
that high levels of androgens might have a detrimental effect on the endometrial function 
resulting in miscarriages 90. Elevated androgen levels and increased number of androgen 
receptors in the endometrium might be, partly, responsible for the poor reproductive 
performance 91. Increased androgen levels in PCOS women may originate from the 
ovaries or the adrenals. Elevated androgen levels may directly or indirectly influence 
early pregnancy outcome (Table 4). 
 
3) Insulin resistance 
Women suffering from recurrent pregnancy loss are more insulin resistant (IR) than age, 
weight and race matched controls 92. Anovulatory PCOS women are more IR than weight 
matched ovulatory PCOS women 60. The majority of PCOS patients are obese.  
Exercise and weight loss, will reduce insulin resistance and result in better 
reproductive health. Weight loss (mean 10.2 kg) in 67 obese infertile women, of whom 75 
% had PCOS, resulted in live born babies in 67% of the women 62. 
Hyperinsulinaemia might affect pregnancy outcome through enhanced androgen 
production both in the ovaries 57 and the adrenals 66. The androgen milieu interferes with 
normal endometrial function and development 90. Insulin stimulates PAI-1 synthesis 93 
and increased PAI-1 activity has been demonstrated in PCOS women with miscarriages 
94.  
Both obese and lean PCOS women are more IR than weight matched controls 75, 
and obesity worsens IR. IR has a negative influence on fertility and seems to result in low 
conception rate 63. In a study of 383 IVF/ICSI treated women, EPL was higher in obese 
24  
 
 women than in lean ones. Obesity seems to be an independent risk factor for EPL 95. 
Wang and colleagues claim that a high risk of spontaneous abortion in PCOS is related to 
a high prevalence of obesity 96 (Table 5). 
 Glycodelin is a glycoprotein produced by the secretory glands of the decidualized 
endometrium. Decreased serum concentration of glycodelin is associated with early 
pregnancy loss and recurrent spontaneous abortions 97,98. PCOS women have low 
glycodelin concentrations, in particular when they experience EPL.99.  Hyperinsulinemia 
seems to suppress endometrial secretion of glycodelin 99. This could explain the 
deleterious effect of hyperinsulinemia on pregnancy. 
In conclusion, increased insulin resistance and elevated insulin levels may be a 
metabolic mediator for reduced fecundity both in PCOS women and in obese women 
generally. Improving insulin sensitivity and reducing circulating insulin levels seem to 
improve fertility.  
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X PCOS and pregnancy complications in the second and third 
trimester 
 
When evaluating pregnancy outcome data for pregnancies achieved by assisted 
fertilization, clinicians became aware that pregnancies in PCOS women comprised a 
special group, different from other groups receiving assisted fertilization. 
 The incidences of pre-eclampsia and gestational diabetes mellitus (GDM) among 
PCOS women have been studied, but the results were contradictory. This may be due to 
classification difficulties, since the criteria used for diagnosing PCOS were not uniform, 
and the criteria for diagnosing GDM also differ between countries. It may also be due to 
the fact that the PCOS populations studied differ with respect to body mass index, parity, 
race and single vs. multiple gestations. The control groups, with whom the PCOS 
populations were compared, were also heterogenic (i.e., normal controls, or non-PCOS 
patients who received fertility treatment). With a few exceptions, the studies were 
retrospective. A review on studies dealing with the association between PCOS 
pregnancies and GDM, pre-eclampsia and prematurity follows in Table 6 to Table 9. 
 
a) PCO, PCOS and gestational diabetes mellitus 
The relationship between PCO and GDM in a prior pregnancy has been studied in 
Sweden, Finland and the United Kingdom 100-103 (Table 6). The control groups consisted 
of women with previous normal pregnancies. The studies were performed 6-54 months 
post partum. In all, 189 women with previous GDM were included. The prevalence of 
PCO ranged from 40% to 50 % in the GDM groups and from 3% to 27% in the control 
groups. Holte et al. reported that women with previous GDM were more obese, hirsute 
and had more irregular menstrual bleedings than the control group 101. Kousta et al. found 
that women with previous GDM were more obese and more insulin resistant than normo-
glycemic controls 103. No differences were observed in androgen levels. Koivunen et al., 
however, reported that former GDM patients were not only more insulin resistant, but also 
had higher adrenal androgen levels than age and parity matched controls 102.  
 These data indicate that as many as 30-50% of women with a history of GDM 
would meet the diagnostic criteria of PCOS, and that there is an association between 
GDM and PCOS. This association could, however, be explained by obesity. 
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 In most studies, where the PCOS population had similar BMI as the control group, 
PCOS women did not have an increased risk for GDM 104-107. Radon et al., however 
reports an increased prevalence of GDM among PCOS women compared to age and 
weight matched normal controls 108. Mikola et al. found that PCOS was an independent 
predictor for GDM in singleton pregnancies 109. The reported incidences for GDM in 
PCOS women vary from 7.5% to 41% 107-111 (Table7). The reported incidence for normal 
controls in the same studies vary from zero to 9% 107-111 (Table 7).  
 There seems to be a higher incidence of GDM in PCOS women, despite the 
observation that these patients increase their insulin secretion during pregnancy more than 
non-PCOS patients 112. The increment of insulin secretion seems to be similar in PCOS 
women, who develop GDM, and those who do not. This is in accordance with the 
hypothesis that insulin resistance is more important than the capacity for insulin secretion 
in the pathogenesis of GDM in PCOS women. 
Women with PCOS should be routinely screened for GDM in pregnancy 
according to the recommendations from The Royal College of Obstetrics and Gynecology 
113. 
There is a need for standardized, prospective studies in which age, BMI and 
multiple gestations are accounted for to estimate the prevalence of GDM in PCOS 
women. 
 
b) PCOS and pre-eclampsia 
Diamant and colleagues were the first to study the prevalence of pre-eclampsia (PE) in 
PCOS patients 114. In a retrospective study, they found that PCOS women compared to 
normal primipara had a three fold higher risk for PE. De Vries et al. found similar results 
in a study of PCOS women and age and parity matched controls 115. Mikola et al., 
however, found that the increased risk of PE was confined to nulliparous women 109. 
Gjønnæss concluded that the high prevalence of PE (13 %) was related to high BMI 116.  
One other Norwegian study reported a 22% incidence of PE among insulin resistant 
PCOS patients 117. The only prospective study found a high rate of PE in PCOS women 
compared to normal controls 111. Diverging results make the conclusion difficult. It seems, 
however, that the symptoms of pre-eclampsia commence relatively late in gestation and is 
of a mild form in most PCOS pregnancies (Table 8). 
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 c) PCOS and preterm delivery 
There has been little focus on the possible association between PCOS pregnancies and 
preterm delivery. Studies dealing with pregnancy outcome in PCOS women sporadically 
present figures for preterm delivery, but somehow, there have been no focus on this topic. 
In five central studies on pregnancy outcome in PCOS women with singleton pregnancies 
the preterm delivery rate is remarkably high 84,105,109,116,117 . Gjønnæss reported 10% 
preterm delivery rate before 32 gestational weeks in PCOS women previously treated 
with ovarian wedge resection 116. Bjercke et al. observed 23% preterm birth rate (<37 
weeks) among PCOS women after infertility treatment 117. These two studies represent a 
Norwegian population with good socioeconomic standards, but they were from two 
different hospitals and 14 years apart. The prevalence of preterm deliveries (< 37 weeks) 
in Norway has remained stable around 6-7 % during this period of time. Hence, in 
Norwegian PCOS women the preterm delivery rate appears to be three fold increased. 
The preterm delivery rate in Venezuela among PCOS women was also surprisingly high 
(33% <37 weeks) 84. 
 In contrast, two retrospective studies from the Czech Republic and Finland 
observed no increased risk for preterm delivery in PCOS patients 105,109 (Table 9). 
 
 
XI  Androgen and estradiol levels in normal pregnancy  
 
Steroid hormone measurements in pregnancy were used for fetal surveillance and 
monitoring of fetal wellbeing in the 1960s and 1970s, before ultrasonography and other 
more informative tools became the method of choice.  
Placenta plays a major role in steroid hormone synthesis and elimination. Fetal and 
maternal DHEAS is metabolized to estrogens via androstenedione and testosterone. The 
process converting androgens to estrogens is called aromatization. 
DHEAS:  DHEAS in maternal serum is reduced in pregnancy as a result of a 6-10 fold 
increased clearance 118. At delivery, however, maternal DHEAS levels are increased 
compared with earlier in pregnancy 119. This might reflect both increased production in 
the adrenals as a result of stress and / or decreased clearance in connection with delivery. 
DHEAS concentration is lower in the umbilical vein compared to maternal serum. 
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 Androstenedione:   Androstenedione levels increase slightly throughout pregnancy and 
reaches a maximum at delivery 118. Androstenedione levels in the umbilical vein are about 
1/3 of the concentration in maternal serum. At birth, androstenedione levels in umbilical 
vessels are higher in boys than in girls 120.  
Total testosterone: The total testosterone concentration increases about 30% during 
pregnancy and is at its peak at delivery 118-120. Fetal sex does not affect testosterone levels 
in either maternal or umbilical cord serum 118-120. Ninety-eight percent of the total 
testosterone is bound to SHBG and albumin and only 2 % is free and assumed to be 
biologically active 121. 
SHBG: Estrogens stimulate the synthesis of SHBG in the liver, and there is a 3-4-fold 
increase of SHBG in the second half of the pregnancy 118. 
Free testosterone levels:  FT is consistently low throughout pregnancy. Fetal FT is 
higher than maternal levels at delivery 122. 
Estradiol: Estradiol is increased throughout the pregnancy, and in particular between 
week 20 and 35 because of enhanced synthesis of DHEAS in the increasing mass of 
placental tissue 118. At the end of pregnancy, the placental capacity for aromatization 
decreases as a sign of placental ageing. Possibly, this explains the increased maternal 
levels of testosterone and androstenedione at the end of pregnancy. 
 
 
XII Androgen excess, pregnancy complications and fetal programming 
 
It has been proposed that fetal growth restriction resulting from placental dysfunction, 
maternal stress or malnutrition increases the risk for cardiovascular disease, diabetes 
mellitus type-2 and hypertension in adult life 123-126.  
 Imprinting is when expressions of genes are permanently altered, so that the same 
genotype is expressed as different phenotypes. 
The effect of excess androgens in pregnancy has been studied in animal models. It 
has been speculated on a possible mechanism, of excess androgens, on pregnancy 
complications and on fetal programming. This opens the possibility that increased fetal 
androgen exposure is the common pathogenic pathway to cardiovascular disease, diabetes 
mellitus type-2 and PCOS in adult life. 
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 Eisner et al. demonstrated that female offspring of rhesus monkeys exposed to 
androgen excess early in pregnancy had impaired beta-cell function as adult animals with 
decreased ability to respond to hyperglycemic stimulation. Monkeys treated with 
testosterone in late pregnancy gave birth to offspring who developed high BMI, increased 
insulin resistance and excess visceral fat 69. By adulthood, prenatally androgen exposed 
rhesus monkeys demonstrated increased LH secretion, anovulation, hyperandrogenism 
and polycystic ovaries, and this condition was very similar to PCOS in man 127. These 
studies suggest that excess prenatal androgen exposure can be responsible for fetal 
programming of impaired insulin secretion and action. 
Prenatal testosterone excess in sheep caused fetal growth restriction and postnatal 
catch-up growth 55. Increased testosterone levels in ewes were associated with increased 
levels of IGFBP-1 and IGFBP-2 in the fetus post natally. Both IGFBP 1 and IGFBP 2 are 
inversely associated with fetal growth. Decreased IGF-1 in humans are early markers of 
future adult diseases, such as type 2 diabetes and cardio-vascular diseases 128.  
The intriguing question is, if excess androgen exposure in utero is a possible 
common pathway, where do these androgens come from? Finally, what are the 
mechanisms by which increased prenatal fetal androgen exposure leads to growth 
restriction?  
 
a) Placental dysfunction 
Placental dysfunction, leads to reduced utero-placental blood flow and fetal growth 
restriction. In baboons, reduced utero-placental blood flow resulted in an increase in fetal 
androstenedione, a precursor for testosterone 129.  
In an in vitro study, using three placentas from mothers with small for gestational 
age (SGA) infants and three placentas from mothers with appropriate for gestational age 
(AGA) infants, the placentas were perfused with DHEAS 130. There was an accumulation 
of androstenedione and testosterone and low estrone and estradiol levels in the placental 
fluid from the SGA infant placentas. In placentas from AGA pregnancies, no 
accumulation of androgens occurred. In an in vivo study, DHEAS was administrated to 
pregnant women with suspected SGA infants 131. Serial measurements of androgens and 
estrogens were performed for four hours. Mothers, who subsequently gave birth to SGA 
infants, had higher levels of androstenedione and testosterone measured in venous blood 
following DHEAS administration compared to those with AGA infants. This finding 
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 indicates that dysfunctional, damaged or sub optimally functioning placentas have 
reduced capacity to aromatize androstenedione and testosterone to estrogens. 
In humans, elevated androgen levels in utero is seen in fetuses with congenital 
adrenal hyperplasia (CAH) 132. In adult women with CAH, 80% have PCO 133. There is 
also evidence that exposure to excess androgen in utero programs the hypothalamic-
pituitary axis to hypersecretion of LH. Elevated LH levels and disturbed pulsatory pattern 
of LH is seen in anovulatory PCOS women 56.  
In conclusion, there is evidence that dysfunctional placentas can create androgen 
excess in utero, which in turn has a potential to modulate beta-cell function and insulin 
sensitivity, and to alter the hypothalamic-pituitary axis function concerning LH-secretion. 
In addition, excess androgens without placental dysfunction can result in growth 
restriction of the animal fetus.  These alterations might result in adult diseases connected 
to the metabolic syndrome and PCOS. 
 
b) Pregnancy complications and excess androgens in humans 
Androgen excess has been investigated and described in different pregnant populations 
with different pregnancy complications. Most studies have focused on PE, PCOS 
pregnancies and GDM. 
 
1) Pre-eclampsia 
In searching for the etiology of pre-eclampsia, several studies have investigated the 
steroid hormone levels in pre-eclamptic women 134-141. Most, but not all studies, 137,139 
report elevated maternal androstenedione and testosterone in pre-eclamptic pregnancies in 
the third trimester or at delivery 134-136,138,140,141. It has been hypothesized that elevated 
testosterone levels are involved in the pathogenesis of PE. Jiricek et al. demonstrated that 
androstenedione levels correlated positively to blood pressure and uric acid levels in PE 
women 138. The more severe the PE was, the higher were the androstenedione levels. 
Carlsen and colleagues found that women who eventually developed PE, had elevated 
androstenedione and testosterone levels already in the early second trimester 136. It is not 
known whether the elevated androgens are pathogenic factors for the development of PE 
or a result of a dysfunctional placenta. One important question is if maternal serum levels 
of androgens reflect the fetal environment. 
 
2) Polycystic ovary syndrome 
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 Hyper-androgenemia is one of the cardinal characteristics of non-pregnant PCOS women.  
The androgen status in pregnant PCOS women is, however, scarcely studied. Sir-
Peterman and colleagues examined 20 pregnant PCOS women and 26 normal pregnant 
women at gestational weeks 10-16 and later at gestational weeks 22-28 111. DHEAS, 
androstenedione, testosterone and FTI tended to be higher in early pregnancy and were 
significantly higher in later pregnancy in PCOS women.   
 
3) Gestational diabetes mellitus 
In in vitro studies, insulin and IGF-1 regulate steroidogenesis in the human placenta 
137,142,143.  Insulin stimulates 3-beta-hydroxysteroid dehydrogenase leading to increased 
synthesis of progesterone from pregnenolone 142. Progesterone is further converted to 17-
OH-progesterone and androstenedione. The same enzyme 3-beta-hydroxysteroid 
dehydrogenase facilitates the conversion of DHEA to androstenedione.  Insulin also 
inhibits the aromatization of androstenedione to estradiol 143. Theoretically, insulin acting 
by all three mechanisms, could lead to elevated androstenedione and testosterone levels in 
pregnant women.  Dokras and colleagues demonstrated that high insulin levels during 
OGTT in pregnant women correlated to high total testosterone and high free testosterone 
levels 144. Amniotic fluid from insulin treated diabetic mothers had higher testosterone 
levels than amniotic fluid from normal pregnant women 57.  
Insulin resistance and GDM are frequent in PCOS pregnancies, and insulin levels are 
higher in pregnant PCOS women than in normal pregnant women 111. Hence, elevated 
insulin levels could explain the elevated androgen levels in pregnant PCOS women.  
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XIII  Metformin 
 
a) History 
Galega officinalis or French lilac is a perennial herb that blooms in July and August in 
most of Europe. It can be grown as far north as Trondheim. The extract of Galega 
officinalis contains isoamyline guanidine, a hypoglycemic compound, which was used to 
treat diabetes mellitus in medieval Europe 
145,146. The biguanide metformin was 
discovered in the 1950s to have hypoglycemic 
effect. Two guanine molecules that are di-
methylated make up metformin. In 1957 
metformin was introduced as an agent for 
treatment of diabetes mellitus type-2. The use 
of metformin was restricted during the next 
decades because of reports of deaths 
associated to lactic acidosis during metformin 
treatment.  
The drug had a renaissance in the 1990s, 
when metformin was proven to be particularly  
useful in the treatment of diabetes mellitus type 2. 
Linnean herbarium. Swedish 
Museum of Natural History. 
 Other manifestations of metabolic syndrome could also be treated with metformin.
 
b) Absorption 
Metformin is mainly absorbed from the jejunum 147,148. Absorption of an oral dose is 
incomplete, about 20-30 % of metformin passes out with feces. Oral bioavailability of 
500-1500 g metformin is estimated to be 50-60 %. Absorption is complete within 6 hours 
of administration 147-149. Peak plasma concentrations in healthy volunteers are reached 
within 2 hours 147,148 and estimated half-life is 2.8 hours 149. Co-administration of food 
slightly decreases the rate and extent of metformin absorption 150. 
 
c) Metabolism and elimination 
Metformin is water-soluble and is rapidly eliminated by renal excretion due to active 
tubular secretion. Renal clearance of metformin correlates well to creatinine clearance 
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 both in healthy volunteers and patients with kidney disease. Thirty to forty percent is 
recovered in urine after oral administration. Metabolites of metformin have not been 
detected, and metformin does not bind to plasma proteins 147,149,151. 
 
d) Metformin action 
In non-diabetic patients, metformin does not influence blood glucose levels 152-154. 
In patients with diabetes mellitus type-2, metformin lowers fasting blood glucose 
and improves glucose tolerance. The anti hyperglycaemic activity of metformin is 
achieved by stimulation of peripheral glucose uptake, reduced hepatic gluco-neogenesis 
and to a minor degree delayed intestinal absorption 155. Metformin has a major effect on 
hepatic gluco-neogenesis. In non-diabetic subjects metformin has been demonstrated to 
lower cholesterol and LDL/HDL cholesterol ratio 150,156. 
A recent study suggests that the mechanisms of action of metformin might be 
through its activation of AMP- activated protein kinase 157. 
Long-term metformin therapy moderately impair intestinal absorption of vitamin 
B12 in 30-46 % of the patients 158. The reduced absorption of vitamin B12 and folate, leads 
to increased homocysteine levels 159. Homocysteine is the only cardiovascular risk factor 
adversely affected by metformin treatment. Megaloblastic anemia is rare in long-term 
metformin therapy 160,161, and peripheral neuropathy has not been reported. In some, but 
not all studies, reduced levels of serum folate has been demonstrated after metformin 
treatment 159,162. 
 
e) Adverse effect 
Gastrointestinal side effects occur in about 20 % of patients. Adverse effects are usually 
transient and resolve within one month of treatment, but 5 % of the patients cannot 
tolerate the drug. Gastrointestinal side effects, such as bloatedness, nausea, vomiting, 
diarrhea, constipation and metallic taste are most frequent 163. Increasing the dose slowly 
and taking the drug together with food, can diminish side effects 155. A severe and feared 
adverse effect is the development of lactic acidosis. This occurs in less than 1 in 10 000 
patient years, and it has never been observed when contraindications to metformin 
administration is adhered to 155. The contraindications to metformin are impaired renal 
and hepatic function, alcohol abuse, and serious cardiovascular and pulmonary diseases 
155. These are all conditions that predisposes to lactic acidosis per se. 
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XIV Metformin treatment in non-pregnant PCOS women 
 
Since the first report on successful treatment of PCOS women with metformin for a 
decade ago 164, many trials have been performed, and metformin treatment of PCOS 
women has become widespread. However, large well-designed studies are scarce, and few 
studies have lasted longer than six months. Many questions are unanswered. Should all 
PCOS patients be treated with metformin? If not, how shall we select the women who will 
benefit from treatment? Which symptoms should or could be treated and for how long 
time? What are the long-term effects of metformin in PCOS? Most review articles 
conclude that, large randomized controlled trials are needed. One review from the UK´s 
National Institute of Clinical Excellence states that metformin can be used as adjuvant 
treatment to general lifestyle improvements, or in combination with clomiphene in 
women who have failed to ovulate on clomiphene alone 165. 
 The metformin dosage used in PCOS treatment varies between studies. Most 
studies have used doses of 500 mg three times daily or 850 mg twice daily.  
 
a) Effect on menstruation 
Uncontrolled observational studies report restored regular menses in approximately 62% 
of PCOS women with irregular cycles 166. Five RCTs reported significant improvement in 
menstrual cycles 167-171. However, one trial found minimal or no difference in menstrual 
patterns 172. 
 
b) Ovulation induction 
Nine studies have evaluated the effects of metformin on ovulation 66,173-180. Four of these 
were RCTs 173,176-178. The combined data from all nine studies indicate that around 60% of 
previously anovulatory and mainly obese PCOS patients ovulated on metformin 
treatment. The restoration of regular menses and ovulations in these patients were seen 
within 3 to 6 months 166. Harborne et al. reviewed seven RCTs with respect to ovulation 
induction 167,168,173,178,181-183. She concluded that one additional ovulation was attained in 
every 5 month interval with metformin compared to placebo 184.  Lord et al. reviewed 
seven placebo controlled trials and found that the odds ratio for metformin treated PCOS 
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 women to ovulate was 3.88 compared to placebo treated women 113. Metformin also 
seems to induce ovulation in normo-androgenic anovulatory women 185. 
 Nestler and colleagues evaluated the effect of metformin combined with CC. They 
concluded that metformin in addition to CC enhanced ovulation in obese PCOS women 
178. The odds ratio for ovulation was 4.41 in studies where metformin was combined with 
ovulation induction agent vs. ovulation induction agent alone. 113. Non-obese PCOS 
women seemed to respond better to metformin treatment than obese PCOS women 171. 
 
c) Pregnancy and live birth rate 
There are no available data supporting improved pregnancy rate for metformin treatment 
alone 113,166,186. However, in overweight CC resistant PCOS women, six-months 
metformin treatment resulted in 32 live births among 54 women while 20 live births were 
achieved in 55 women treated with ovarian diathermy 185,187.  Metformin combined with 
CC increased ovulation and pregnancy rate compared with CC alone 166. Among normal 
weight PCOS women, pre-treatment with metformin prior to conventional IVF/ICSI tends 
to improve pregnancy rates 188.  
The impact of metformin on live-birth rate has not been proved.  
 
d) Effects on weight reduction 
Out of seven RCTs, which had weight as endpoint, six demonstrated reduction of body 
weight with metformin treatment compared with placebo 184. The studies lasted from one 
to six months and the average reduction in BMI was 4%. However, in a systematic review 
and meta-analysis of RCTs, Lord et al. concluded that there was no evidence that 
metformin caused weight reduction in PCOS women 113. The most recent prospective 
randomized study, which had BMI as a main outcome measure, reported that metformin 
significantly reduced body weight during an eight-months period of treatment. Weight 
reduction seems to be dose-related in obese PCOS women 189. 
 
e) Effects on hirsutism 
Six trials have examined the effect of metformin on hirsutism 113,167,168,190-193. Three trials 
demonstrated a statistically significant, but small reduction in the Ferriman-Gallwey 
score. The other three trials did not find any effect. The studies were small and had a short 
follow up time. Recently, a long-term RCT evaluated hirsutism as primary endpoint. Both 
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 Ferriman-Gallwey score, mean hair diameter and patient perception showed that 
metformin had an effect on moderate to severe hirsutism in a 12-months perspective 184. 
  
f) Effects on acne 
There is essentially no data available. 
 
g) Effects on androgen levels 
In seven RCT the average reduction of androgen hormone levels (free testosterone, free 
androgen index and total testosterone) were around 20%, with wide variations, in the 
metformin groups 167,168,173,178,181-183. The data on SHBG are inconclusive 184.  
 
 
XV.  Safety aspects of metformin use in pregnancy  
 
The present knowledge about the effect of metformin on the fetus is mainly based on 
animal studies, mice embryo experiments, case reports and clinical observations. Some 
reports are almost 45 years old, and the quality of the studies varies. The American Food 
and Drug Administration classifies metformin as a Category B drug, which is defined as: 
“Either animal-reproduction studies have not demonstrated a fetal risk but there are no 
controlled studies in pregnant women or animal reproduction studies have shown an 
adverse effect (other than a decreased fertility), that was not confirmed in controlled 
studies in women in the first trimester (and there is no evidence of risk in later trimesters) 
194. 
 
a) Animal studies 
Four studies in rat and mouse embryos have been published. Two studies from 1961 
report that metformin passes the placenta 195, but it was not teratogenic when  
administered in high doses to pregnant rats 196 (Table 10). Two more recent studies on 
whole mouse embryo cultures, showed no teratogenic or toxic effect on embryo 
development 197,198, although Denno et al. reported delayed closure of the neural tube 198 
(Table 10). 
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 b) Studies on diabetic women 
Placental passage: The first report on metformin passage through the placenta was based 
on detection of metformin in the amniotic fluid from two women who had used 
metformin in pregnancy 199. Metformin was not found in fetal cord blood. A laboratory 
study of placentas from eight healthy women, reported that metformin did not influence 
glucose transport or uptake 200. Hague et al. found metformin in cord blood from seven 
diabetic mothers 201. 
Possible teratogenic effects: Any reported teratogenic effect of metformin should be 
evaluated with care. Most studies have been retrospective, descriptive and the prospective 
ones are not randomized. Until recently, the use of metformin in pregnancy was restricted 
to patients with diabetes mellitus type-2. Thus, the study populations consist of women 
with high risk for pregnancy complications and congenital fetal malformations. Diabetic 
mothers have higher incidence of fetal anomalies, possibly due to hyperglycemia in early 
pregnancy. The treatment period (pregnancy weeks) and the dosage used vary between 
different studies. Some of the studies were conducted in developing countries with 
considerable socioeconomic problems 202,203 (Table11).  
There is no evidence of teratogenic effects of metformin on the human fetus 
(Table11). When compared with other diabetic women, congenital malformations were 
similar or fewer in the offspring of metformin treated women 199,202-204.  
Perinatal morbidity and mortality: Except for one study 205, perinatal mortality and 
morbidity seem to be similar or lower in metformin treated diabetics compared with diet 
or insulin treated diabetics 202-204. Hellmuth et al. reported increased prevalence of pre-
eclampsia and perinatal mortality in metformin treated versus insulin or sulfonylurea 
treated diabetic women 206. This study was retrospective and lasted for decades, and 
women in the metformin group were significantly more obese than women treated with 
sulphonylureas or insulin.  
 
c) Studies on PCOS women. 
Glueck and colleagues reported on a large number of PCOS patients treated with 
metformin in pregnancy 207. Until April 2004, they had prospectively followed 126 PCOS 
women with 151 fetuses. All the women used metformin at the time of conception. The 
offspring of PCOS women were compared to gender specific data from the general 
American population, and among the 126 live born babies, they reported only two 
congenital birth defects; one sacrococcygeal teratoma and one tethered spinal cord. 
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 Metformin did not influence birth length and weight, growth or motor-social development 
in the first 18 months of life.  
In conclusion, so far, there is insufficient evidence to decide whether or not 
metformin has teratogenic effects (Table 10 to Table 12). 
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XVI  Background of the studies 
 
In 1998, I heard a very inspiring lecture about PCOS, by Dr Sven M. Carlsen. The 
endocrinological approach to PCOS was a new aspect for me, and many of my colleagues 
at the Department of Obstetrics and Gynecology. After several creative discussions we 
agreed to initiate a small study involving 45 non-pregnant PCOS women, followed up and 
treated for 14 weeks 208. This successful co-operation was continued by a six-months 
study on 50 non-pregnant PCOS women 209. The first paper in this thesis is based on these 
two studies. 
 Being an obstetrician and gynecologist, it was natural to focus on PCOS and 
pregnancy. In 2000, when we planned the study, the general scientific focus was on 
problems connected to infertility treatment. The reports of Velazquez and Glueck on 
metformin treatment of pregnant PCOS women were unpublished 84,210. The few studies 
investigating pregnancy complications in PCOS women indicated an elevated risk for 
gestational diabetes and pre-eclampsia. We suspected that hyperandrogenemia was 
involved in the pathogenesis. The idea emerged to treat PCOS women with metformin 
throughout pregnancy, hypothesizing that it would reduce maternal androgen levels, and 
thus, influence pregnancy outcome.  
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XVII Aims of the studies 
 
 
Study I: 
1) To investigate the clinical, biochemical and ultrasonographic characteristics of non-
pregnant, Scandinavian PCOS women and to evaluate possible differences between 
eumenorrhoic and oligoamenorrhoic PCOS women 
 (Paper I)  
 
 
Study II: 
1) To investigate possible effect of metformin on androgen levels in pregnant PCOS 
women (Paper II) 
 
2) To investigate a possible effect of metformin on pregnancy outcome in PCOS women 
(Paper II) 
 
3) To investigate the trans-placental passage of metformin in PCOS women  
(Paper III) 
 
4) To analyze if metformin influenced the acid-base status of the newborn  
  (Paper III) 
 
5) To investigate a possible effect of metformin on C-reactive protein levels and indices 
of coagulation factors and fibrinolysis in pregnant women with PCOS  
(Paper IV) 
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 XVIII Material and methods 
 
Paper I 
In two prospective studies 208,209, we used identical inclusion and exclusion criteria and 
definition for PCOS. Clinical, biochemical and ultrasonographic data from screening 
consultations in these two studies are the underlying material for the present paper.  
Inclusion criteria were polycystic ovaries (defined as ≥ 9 sub-capsular follicles 
with a diameter of 3-8 mm), identified by transvaginal ultrasonography, and age between 
18 and 40 years. In addition, at least one of the following criteria had to be fulfilled; 
testosterone > 2.5 nmol/l, SHBG < 30 nmol/l, fasting C-peptide > 1.0 nmol/l, oligo-
amenorrhea, or hirsutism, judged clinically as male pattern excessive growth of body hair. 
Exclusion criteria included pregnancy, breast-feeding, known liver disease, alanine 
aminotransferase > 60 IU/l, creatinine > 130 µmol/l, known alcohol abuse, diabetes 
mellitus and treatment with oral glucocorticoids. Congenital adrenal hyperplasia was 
excluded by 17-hydroxyprogesterone measurements.  
We collected data from 95 PCOS women and we excluded 15 patients from the 
analyses. Six women were excluded because of hormonal contraception use at the time of 
screening evaluation, and six because of BMI< 25 kg/m2. In one woman ovarian 
insufficiency has been overlooked and two women was not fasting when blood samples 
were drawn.  
The remaining 80 women were recruited between December 1999 and June 2001 
from the gynecological or endocrinological outpatient clinics at Trondheim University 
Hospital or by advertisement in the local newspaper. All participants presented one or 
more of the following clinical problems; anovulatory infertility, oligoamenorrhea or 
hirsutism. 
Retrospectively, we evaluated the participating patients according to the 
“Rotterdam Consensus” criteria from 2003 and found that all women met the criteria for 
PCOS according to the new guidelines. 
 
Paper II – IV 
These three papers are based on a study population of 40 pregnant PCOS women with 
singleton pregnancies included in a RCT. Two women withdrew within two weeks after 
inclusion, because of motivation failure. Thirty-eight women completed the study. The 
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 participants were recruited from October 2000 to March 2003 from the gynecological and 
infertility outpatient clinic. Two of the 38 women, also participated in study I (Paper 1) 
described above.  
The diagnosis of PCOS was based on the criteria described in Study 1. All the 
patients met the Rotterdam criteria for PCOS, when this was assessed retrospectively. 
Inclusion criteria were PCOS diagnosis, singleton viable fetus between gestational week 5 
and 12 and maternal age of 18 – 40 years at inclusion. We chose to include a broad 
spectrum of PCOS patients with no restrictions regarding mode of conception and 
metformin pretreatment.  
To avoid clustering of participants in the trial, a pharmacist performed 
stratification according to metformin use at conception and the patients were block 
randomized. Blood samples were drawn at inclusion and at gestational weeks 19, 32 and 
36. Oral glucose tolerance test were performed at inclusion and at gestational weeks 19 
and 32. When pregnancy complications occurred, all patients were examined, followed up 
and treated according to clinical routines in Norway. 
Blood samples 
Testosterone and androstenedione analyses: 
For testosterone analysis, we initially used the commercially available Elecsis 2010 
method, which was the routine method used at the Department of Clinical Chemistry, The 
University Hospital of Trondheim. Elecsis 2010 (Roche-Boehringer-Mannheim) is a 
competitive ELISA method. This method is automated, quick and relatively inexpensive. 
Unfortunately, we were not aware of the report by Tayëb and colleagues 26. She found 
that none of the ten most used, commercially available immunoassay methods were 
sufficiently reliable for the low testosterone concentrations seen in women. Most methods 
overestimate low concentrations of testosterone. Elecsis 2010, however, underestimate 
testosterone values in women.  
In addition, we suspected that androstenedione values measured by Immulite 
2000, an automated immunoassay, were imprecise. According to advice from reviewers 
and specialists in clinical chemistry, we reanalyzed our material. We chose Diagnostic 
Products Corporation (DPC) Coat-A-Count (Los Angeles, CA). This method is a RIA 
method, which turned out to slightly overestimate the low testosterone values compared to 
isotope-dilution gas chromatography-mass spectrometry (ID/GC-MS) in the study of Tayëb. 
This overestimation is assumed to be an effect of interference with other androgen 
metabolites. Torjesen reported that RIAs agreed well with the ID/GC-MS, although 
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 interferences happen 211. To solve this problem an extraction was performed before 
testing. 
Analysis of metformin concentration in serum 
Immediately after, and independently of the mode of delivery, blood samples were drawn 
from the antecubital vein from the mother, and samples both from the umbilical artery and 
vein. Information, about the last capsules of metformin taken before delivery, was 
registered. Metformin in serum was analyzed by liquid-chromatography-mass 
spectrometry method. 
 
Statistical analyses 
 
Paper I and II 
Values are reported in means and standard deviations for continuous normally distributed 
variables. Categorical variables are presented as numbers and percents. Differences 
between the study groups were compared with two tailed t-tests for independent samples. 
Non-parametric tests, Mann-Whitney, for independent sample were used where normality 
could not be assured. Pearson’s correlation coefficient was used for correlation analyses. 
Simple linear regression analyses were used to investigate linear trends. Fisher’s exact test 
was used for evaluation of discrete data. Data were analyzed according to the intention to 
treat principle (Paper II). 
 
Paper III and IV 
Values are reported as medians and inter quartile ranges (IQR). For correlation analyses 
Spearman’s rank test were used. In Paper IV values are log transformed to overcome 
uneven distribution. General linear model was used for repeated measures (Paper IV). 
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XIX Main results  
 
Study I  
“Clinical, biochemical and ultrasonographic characteristics of Scandinavian women with 
PCOS” (Paper I) 
1) Except for thicker endometrium and smaller ovarial volume in regularly 
menstruating women, there were no clinical or biochemical differences between 
eumenorrhoic and oligoamenorrhoic PCOS women. There was a positive linear 
trend for increasing BMI with increasing number of diagnostic criteria met.  
 
Study II  
“Metformin reduces pregnancy complications without affecting androgen levels in 
pregnant PCOS women: results of a randomized study” (Paper II) 
1) Metformin did not influence androgen levels in pregnant PCOS women.  
2) None of the women in the metformin group experienced severe pregnancy    
complications. Seven women experienced severe pregnancy complications in the 
placebo group. 
 
 “Placental passage of metformin in women with polycystic ovary syndrome” (Paper III) 
2) Metformin passes freely the placenta. At the time of birth, the fetus is exposed to 
therapeutic metformin concentrations.  
3) Metformin does not seem to influence pH levels in the umbilical artery. 
 
“The beneficial effect of metformin on pregnancy outcome in PCOS women is not 
associated with major changes in CRP or indices of coagulation” (Paper IV) 
4) Metformin treatment in pregnancy did not result in major changes in C-reactive 
protein, D-dimer, antithrombin III, activated protein C resistance and activated 
partial thromboplastin time. Protein C increased slightly in the metformin group.
45 
 
  
XX  Discussion and interpretation of the results 
 
Paper I 
In 1999 to 2001, when this study was planned and performed, there was no general 
agreement on the definition of PCOS. We discussed whether or not we should include 
“normal weight” (BMI < 25 kg/m2) PCOS women. There was a widespread opinion, that 
slim PCOS women differed from obese, not only in the pathogenesis of the disease, but 
also in clinical features and prognosis. They might not only represent a subgroup, but 
perhaps a separate entity. Therefore, we chose to include those with BMI above 25 kg/m2.  
Today, however, we would have used the Rotterdam criteria, without selection according 
to BMI.  
 After Carmina and Lobo presented their study results suggesting that almost 75% 
of hyper-androgenic, normally menstruating women had evidence of PCOS 212, we 
decided to assess, if eumenorrhoic and oligomenorrhoic patients differed in clinical or 
biochemical characteristics.  Our study confirmed that normally menstruating 
Scandinavian women can have PCOS and this is important to know in everyday clinical 
practice.  
 There has been, and still are, an ongoing discussion about the implications of 
PCOS on the present and future health of these women. Are these possible implications 
due to PCOS per se, or are they related to other endocrine and metabolic changes 
secondary to overweight and adiposity? The present study seems to strengthen the view 
that obesity is involved in the pathogenesis of PCOS. The severity of PCOS was 
positively correlated with increasing obesity. 
 
Paper II 
This paper was a pilot study with a limited number of participants. The primary aim of the 
study was to investigate possible differences in androgen levels between metformin and 
placebo treated pregnant PCOS women. Power calculations were made from change 
assumptions in testosterone levels. Metformin effects on the pregnancy outcomes were 
secondary outcomes. We assumed that there might be minor differences in clinical 
outcomes. We were very surprised by the results. The pilot study was meant to be a 
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 feasibility study, and to form the basis for power calculations of a full-scale study on 
pregnancy outcome. 
Among women, who had been pregnant before, almost half of the previous 
pregnancies had ended as spontaneous abortions. This is well in line with other 
retrospective reports on pregnancy outcome in PCOS women (Table 2). 
The pregnancy related complications were unexpectedly high among placebo treated 
women. This is so, even if we take in to account that prospective follow-up studies are 
more “accurate” in identifying pathology. We believe that the women included in this 
study had severe PCOS. They sought help for their condition, and they were motivated to 
participate in a study. 
We believe that pregnancies in PCOS women should be regarded as high-risk 
pregnancies. 
We included both normal weight and overweight women independent of mode of 
conception. Women, who conceived on metformin treatment, were also included. As 
metformin treatment has become widespread among Norwegian PCOS women, this 
reflects the real world in clinical practice. Pre-study metformin treatment could 
theoretically have influenced our results. Indeed, nineteen women used metformin at 
conception. Thus, we did a stratified block randomization to control for pre-
randomization use of metformin. 
Eleven of 22 women in the placebo group used metformin at inclusion, and 8 of 18 
women in the metformin group used metformin at inclusion. Even if pre-study metformin 
could influence pregnancy complications, which we do not know, this influence would be 
equally distributed between the two randomized groups.  
The minimum two days “wash-out” period may be insufficient to abolish any 
metformin effects, although t1/2 for metformin is 1.5-4.5 hours in non-pregnant women. 
Only seven women had a “wash-out” period shorter than two weeks. Exploratory analyses 
with exclusion of these seven patients did not change the results materially. 
Metformin was surprisingly well tolerated in pregnancy. None of the participant 
stopped medication, and only six women used reduced dosage. Three of these six women 
received metformin and three received placebo. 
Testosterone and androstenedione measurements were a problem. Isotope-dilution gas 
chromatography-mass spectrometry (ID/GC-MS) is considered as the gold standard. This 
method does not suffer from cross reactivity and matrix effects. It is, however, expensive 
47 
 
 and laborious, and it was not available for us at the time of the study. In Norway, it is still 
not available for androgen analyses in serum.   
Steroid hormones, i.e. androgens are commonly analyzed by commercially 
available automated immunoassays. Immunoassays use either radioimmunoassay (RIA) 
or enzyme-linked immunosorbent assay (ELISA) method for testosterone measurements. 
Traditionally, testosterone immunoassays involve extraction of structurally related 
molecules, which can interfere with the results. 
Testosterone and androstenedione values are presented according to Elecsis 2010 and 
RIA methods after extraction (Table12). Testosterone and androstenedione values 
differed in the two analyzes, but the conclusion is unchanged; metformin does not 
influence androgen levels in pregnant PCOS women. 
 
Paper III 
There is, in the present study, no evidence that metformin has any teratogenic or adverse 
effects on the mother or the fetus. The present study demonstrates that metformin passes 
the placenta to the fetus, and that some hours after ingestion, concentrations tended to be 
higher in the umbilical artery than maternal serum. In adults, metformin is eliminated by 
renal tubular secretion. Hence, one may speculate that metformin is excreted to the 
amniotic fluid and reabsorbed to the fetal circulation by swallowing. This could explain 
the higher concentrations found in the umbilical artery.  
Possible long-term effects of metformin in the offspring are unknown. 
Theoretically, metformin can alter or modulate metabolic pathways in the fetus. It is of 
outmost importance to follow up children exposed to metformin in utero in RTCs.  
 
Paper IV 
Elevated CRP levels in early pregnancy have been associated with pregnancy 
complications such as GDM, pre-eclampsia and fetal growth restriction in non-PCOS 
women. Metformin has been reported to decrease CRP levels in non-pregnant PCOS 
women. Impaired fibrinolytic capacity has been demonstrated in PCOS women.  It was a 
logical step to investigate the possible effect of metformin on CRP levels and coagulation 
indices. However, we found no major effect of metformin on the measured parameters 
that could explain the effect of metformin on pregnancy complications. 
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XXI  Conclusions  
 
We found no major differences in oligoamenorrhoic and eumenorrrhoic PCOS women 
with respect to clinical and biochemical parameters, except for thicker endometrium and 
smaller ovarian volume. Obesity seemed to worsen the clinical presentation of PCOS. 
PCOS is associated with an increased risk for pregnancy related complications. 
The results indicate that PCOS pregnancies should be regarded as high-risk pregnancies. 
Metformin is well tolerated in pregnancy. It seems to prevent pregnancy complications in 
the second and third trimester in PCOS women. Metformin passes the placenta, and the 
fetus is exposed to therapeutic levels of metformin. However, metformin have no major 
effects on androgens, CRP or coagulation factors. How metformin exerts its possible 
effect on pregnancy outcome is unrevealed. 
 
 
XXII  Final reflections and future aspects  
 
One great challenge for future research is to motivate women to participate in 
randomized, placebo-controlled trials. Many women seem to be convinced of the positive 
effects of metformin on pregnancy, by the information they receive from the web, and 
they are not willing to “risk” to end up with placebo in a trial. To communicate and 
interpret scientific results in a sober and nuanced way to a general population is a major 
task and a great challenge. Also doctors should understand that it is unwise to advocate 
metformin treatment in pregnancy before solid, reliable data are available. 
The present data are encouraging, but before routine use of metformin can be 
recommended to pregnant PCOS patients, our results must be confirmed by at least one 
well-designed large-scale study.  
If the results are confirmed by a larger randomized controlled trial, there are still 
many questions to answer: 
• What is the mechanism of action, by which metformin exerts its effect on 
pregnancy complications? What are the pregnancy complications that 
metformin can prevent? 
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 • Which patients should be recommended to use metformin in pregnancy? 
All PCOS women, only those with earlier complications or only obese 
PCOS women? Or just those who conceive on metformin? 
• When should one start and stop the treatment and what is the optimal dose 
that should be used? Should there be given additional folic acid or vitamin 
B12? 
• Are there any negative consequences of stopping metformin use in 
pregnancy?  
• How does metformin influence the offspring on short or long-term basis? 
As long as we do not know the long-term effects of antenatal metformin 
exposure, follow-up of the offspring from clinical trials should be 
compulsory. 
 
As a continuum of my thesis, a prospective randomized, double blind, multi-centre 
study initiated from our department was started up in February 2005. We aim to include 
300 - 350 pregnant PCOS patients, treat them with metformin or placebo and follow them 
throughout pregnancy. The offspring will be followed at least to the age of 18 years. This 
will hopefully provide some of the answers, - and most certainly raise new questions. 
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Table 1.  Early pregnancy loss and PCO 
 
Name of first 
author and year of 
publication 
 
Study design Participants Results Conclusions 
Sagle M 
1988 
Retrospective 56 women with RPL 
11 parous women 
RPL                      ⇒ 82% PCO 
Controls                ⇒ 18% PCO 
High prevalence of PCO among women with 
RPL 
Balen AH 
1993 
Retrospective  1060 IVF pregnancies
 
27 % EPL  
5 % ectopic pregnancies 
PCO                      ⇒ 36% EPL 
Normal ovaries     ⇒ 24% EPL 
Higher EPL rate among women with PCO 
compared to women with normal ovaries 
Watson 
1993 
Prospective 21 women with RPL 
10 multiparous controls 
RPL                      ⇒ 81% PCO 
Controls                ⇒ 10% PCO 
High LH                ⇒ 81% EPL 
High LH among women with RPL 
High testosterone in the RPL group 
Tulppala M  
1993 
Prospective 50 women with RPL 
20 healthy controls 
RPL                      ⇒ 44% PCO 
Controls                ⇒ 12% PCO 
High prevalence of PCO among women with 
RPL 
Clifford K  
1994 
Prospective 500 women with RPL 56 % PCO 
31 % obesity 
32 % sub-fertility 
High prevalence of PCO among women with 
RPL 
Liddell HS  
1997 
Prospective 73 women with RPL 
Mean BMI 24 kg/m2
36 % PCO 
64 % normal ovaries 
PCO in RPL did not predict poor pregnancy 
outcome 
Rai R 
2000 
Prospective 
cohort 
486 RPL RPL                      ⇒ 41% PCO High LH was not associated with high 
miscarriage rate  
PCO morphology did not predict pregnancy 
loss in RPL women conceiving spontaneously 
 
RPL = Recurrent Pregnancy Loss 
EPL = Early Pregnancy Loss 
LH = Luteinizing Hormone 
  
 
 
 
 
Table 2.  Early pregnancy loss and PCOS 
 
Name of first 
author and year of 
publication 
 
Study design Participants Results Conclusions 
Homburg R 
1988 
Prospective  54 PCOS women treated 
with pulsatile LH 
releasing hormone 
41 PCOS women ovulated 
27 PCOS women became pregnant  
11 PCOS women experienced EPL 
High LH levels associated negatively with 
conception and pregnancy outcome 
High rate of EPL in PCOS women 
Glueck CJ  
2002 
Retrospective  40 PCOS women
 
100 pregnancies in 40 PCOS women 
62 % of the pregnancies ended as EPL 
High rate of EPL in PCOS women 
Jakubowicz DJ 
2002 
Retrospective 31 PCOS women 42% EPL High rate of EPL in PCOS women 
 
EPL = Early Pregnancy Loss 
LH = Luteinizing Hormone 
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Table 3.  Early pregnancy loss and LH 
 
Name of first 
author and year of 
publication 
Study design 
 
Participants   Results Conclusions
Homburg R 
1988 
Prospective  54 PCOS women LH  levels lower in those who 
conceived vs. not conceived 
LH levels higher in those who 
miscarried vs. continued pregnancy 
Low LH levels associated both with conception 
and continued pregnancy 
Regan L 
1990 
Prospective   197 women with
spontaneous ovulations 
LH < 10U I/L     88 % pregnant 
                           12 % EPL 
LH > 10 UI/L     67 % pregnant 
                           65% EPL 
High pre-pregnancy follicular phase LH is 
negative for conception and pregnancy outcome 
Watson H 
1993 
Prospective 21 women with RPL 
10 multi-parous controls 
RPL              ⇒  81%  PCO 
Controls        ⇒  10 % PCO 
High LH       ⇒   81% EPL 
High LH among women with RPL 
 
Clifford K 
1996 
Prospective,  
Randomised, controlled 
106 RPL 
 
LH suppression          ⇒ 52% LBR 
No LH suppression    ⇒ 63% LBR 
Pre-pregnancy LH suppression did not improve 
life birth rate 
Rai R 
2000 
Prospective cohort 486 RPL RPL              ⇒  41% PCO High LH was not associated with high 
miscarriage rate  
PCO morphology did not predict pregnancy loss 
in RPL women conceiving spontaneously 
 
LBR = Life Birth Rate 
RPL = Recurrent Pregnancy Loss 
LH = Luteinizing Hormone 
 
 
 
  
Table 4.  Early pregnancy loss and androgens 
 
Name of first 
author and year of 
publication 
Study design Participants 
 
Results  Conclusions
Tulppala M  
1993 
Prospective 50 women with a history of RPL 
20 healthy controls 
Before index pregnancy: ↑ total 
testosterone and DHEAS levels in 
women with EPL vs. successful 
pregnancies 
↑ androgens in women with EPL  
Watson H  
1993 
Prospective 21 women with RPL 
10 multiparous controls 
↑ testosterone in RPL compared to     
controls  
↑ testosterone in the RPL group 
Okon MA  
1997 
Retrospective 43 regularly menstruating women    
with RPL 
18 fertile controls 
 
↑ testosterone, ↑ DHEAS, 
↑ androstenedione, ↑ FTI and 
↓ SHBG in the RPL group vs. controls 
RPL women, with or without PCOS, had 
higher androgen levels than normal controls. 
High androgen concentrations may result in 
abnormal secretory endometrium 
 
RPL  = Recurrant Pregnancy Loss 
DHEAS = Dehydroepiandrosterone Sulphate 
EPL  = Early Pregnancy Loss 
FTI  = Free Testosterone Index 
SHBG  = Sex Hormone Binding Globuline 
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Table 5.  Early pregnancy loss, obesity and insulin resistance 
 
Name of first 
author and year 
of publication 
Study design Participants 
 
Results  Conclusions
Dale PO 
1998 
Prospective 42 IVF treated PCOS women  
 
17 IR PCOS 
25 NIR 
BMI higher in IR PCOS 
Higer FTI and lower SHBG in the IR-PCOS 
IR PCOS had higher cancellation of 
IVF treatment, and lower 
conception rate than NIR PCOS 
Clark AM 
1998 
Prospective 67 obese infertile women completing 
diet and life style program 
20 obese infertile drop outs 
(75% of the participants had PCOS)  
Completing study: ↓ BMI (3.7) and  
                               18% vs. earlier 75% EPL 
                               67% LBR 
Drop outs:              ↓ BMI 0.4 
                               No pregnancies  
Weight loss in obese PCOS women 
improves fertility 
Huber-Buchholz 
M 
1999 
Prospective  18 anovulatory PCOS 
10 ovulatory PCOS 
Weight matched 
Decreased insulin sensitivity and 
increased insulin levels in anovulatory PCOS 
women 
Exercise and sensible eating with 
minimal weight loss improve 
reproductive health in obese PCOS 
women 
Fedorcsak P 
2000 
Retrospective 383 IVF/ICSI patients 
Lean   (BMI < 25) vs. 
Obese (BMI ≥ 25) 
 
12 % EPL in the lean group 
22 % EPL in the obese group 
Obesity is an independent risk 
factor for early pregnancy loss 
Wang JX 
2001 
Retrospective 376 PCOS women of 1018 infertile 
women 
25 % EPL in PCOS High risk of EPL in PCOS could be 
due to obesity 
Craig LB 
2002 
Prospective 74 RPL vs. 74 controls 
Age, race, BMI matched 
Fasting insulin and HOMA-IR higher in the 
RPL group 
Increased prevalence of IR in RPL 
patients 
 
IR  = Insulin resistance  
NIR     = Non-Insulin Resistant 
HOMA-IR = Homeostasis Model Assessment – Insulin Resistance    
RPL    = Recurrent Pregnancy Loss 
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Table 6.  Gestational diabetes mellitus in previous pregnancy and polycystic ovaries 
 
 Name of first 
author and year 
of publication 
Study design Participants Results Conclusions 
 
Holte J 
1998 
Retrospective / 
prospective 
34 former GDM vs. 
36 earlier normal pregnancies 
4.5 years after index pregnancy 
GDM:              41% PCO 
Controls:            3% PCO 
High prevalence of PCO 
among former GDM patients 
GDM + PCO: 50% PIH, 
Higher BMI, higher androgens 
Anttila L 
1998 
Retrospective  31 former GDM vs. 
31 earlier normal pregnant women age and 
weight matched  
6 -16 months after delivery 
GDM:                45% PCO 
Controls:             7% PCO 
Women with PCO had high 
risk for GDM 
Kousta E 
2000 
Postpartum 
follow up 
91 former GDM 
73 normo-glycemic controls 
Twins included 
20 and 29 months post partum 
GDM:    52% PCO vs. 27% controls 
↑ BMI + W/H ratio 
↑ Fasting insulin 
High incidence of PCO among 
GDM patients 
Koivunen R 
2001 
Case control 33 former GDM 
48 age and parity matched controls 
GDM:        40% PCO 
                  Abnormal OGTT 
                  Higher DHEAS 
Controls:   17% PCO 
Women with previous GDM 
have often PCOS and are more 
insulin resistant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI  = Body Mass Index 
GDM  =  Gestational Diabetes Mellitus 
PIH  =  Pregnancy Induced Hypertension 
OGTT  =  Oral Glucose Tolerance test 
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 Table 7.  PCOS and gestational diabetes mellitus 
Name of first 
author and year 
of publication 
Study design Participants Results Conclusions 
 
Wortsman J 
1991 
Retrospective 53 PCOS women  
2306 general pregnancies 
Maternal age and ponderal index similar 
PCOS:       7.5%  GDM   
Controls:   6.6%  GDM    
Macrosomia similar 
No increased risk for GDM in 
PCOS women 
Lanzone A  
1995 
Prospective 12 PCOS 
12 healthy controls  
Increased insulin secretion 
during pregnancy in PCOS 
Increased risk for GDM in PCOS 
women 
Urman B 
1997 
Retrospective 47 PCOS  
100 healthy controls  
Slim population 
PCOS:      13% GDM 
Controls:    2% GDM 
 
Increased risk of GDM and 
hypertensive disorder in pregnant 
PCOS women  
Radon PA 
1999 
Retrospective 
cohort  
22 PCOS 
66 age and weight matched normal controls. 
Not matched for parity 
PCOS:      41% GDM    OR:22 
           ↑ pre-eclampsia  OR:15 
           ↑ compl. deliv.   OR:5.5 
Controls:    3% GDM 
Women with PCOS have increased 
risk for GDM, pre-eclampsia and 
delivery complications 
Fridström  M 
1999 
Case-control  33 PCOS
66 Fertility treated women  
Similar weight. Twin pregnancies included 
 No difference in blood glucose 
levels 
Vollenhoven B 
2000 
Case-control 60 PCOS 
17 hypogonadism 
12 unexplained infertility 
60 BMI, age and race matched controls 
GDM similar in PCOS, controls 
and other infertile women 
No difference in prevalence of 
GDM in PCOS vs. age, BMI and 
race matched controls 
Mikola M 
2001 
 
Retrospective 80 PCOS women with 99 pregnancies 
737 controls 
PCOS:       20% GDM 
Controls      9% GDM 
Increased risk of GDM in PCOS 
women (Explained largely by 
increased BMI) 
Bjercke S 
2002 
  29 NIR PCOS 
 23 IR PCOS compared to 
355 women who received AR 
PCOS:       7.7% GDM 
AR:            0.6% GDM 
GDM is increased in PCOS 
pregnancies 
Glueck CJ 
2002 
Retrospective 72 PCOS pregnancies (obese women) 
No controls 
31% GDM  
 
High rate of GDM in PCOS women 
Sir-Peterman T 
2002 
Prospective  20 PCOS
26 Controls with singleton pregnancies 
PCOS:       15% GDM 
Controls:      0% 
High rate of GDM in PCOS women 
Türhan NÖ 
2003 
Retrospective 38 PCOS 
136 Non-PCOS (random selection) 
Main predictor for GDM is BMI 
>25 kg/m2
High IGT among PCOS women is 
related to obesity 
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 Table 8.  PCOS and pre-eclampsia 
Name of first author and 
publication year 
Study design Participants Results Conclusions 
 
Diamant YZ 
1982 
Retrospective 33 PCOS with 70 pregnancies  
39 anovulatory women with 71      
pregnancies 
1000 nornal pregnant primipara 
PCOS                       28.5% PE 
Anovulatory             16.5% PE 
Controls                      11% PE 
Higher prevalence of PE in PCOS 
Gjønnæss H 
1989 
Retrospective 
 
69 PCOS after LOD  
No controls 
Perinatal mortality:        9% 
PE:                               13% 
GDM:                            8% 
Preterm (< 32 weeks):  10% 
The high prevalence of PE and GDM is 
related to high BMI 
Urman B 
1997 
Retrospective 47 PCOS  
100 healthy slim controls  
 
PCOS:                       25% PIH 
Controls:                     8% PIH 
 
Increased risk of PIH in PCOS women 
Difference between lean PCOS and lean 
controls  
De Vries 
1998 
Retrospective 
 
81 PCOS pregnancies 
81 age and parity matched controls 
PCOS:     26% PIH, 14% PE 
Controls:  25% PIH, 2% PE 
Similar BMI 
PCOS women are at higher risk of PE 
Fridström M 
1999 
Retrospective  33 PCOS
66 No-PCOS   Twins included 
↑ risk of hypertension in the 
III. trimester 
Increased risk of PIH in PCOS women 
Kashyap S 
2000 
Retrospective  22 PCOS 
27 infertile controls  
Singletons 
PCOS:                       32% PIH 
Controls:                  3.7% PIH 
Age, BMI, parity similar 
Increased risk of PIH in PCOS 
Mikola M 
2001 
Retrospective 80 PCOS with 99 pregnancies 
737 controls 
PCOS:                        4% PE 
Controls:                    2% PE 
 
PE and prematurity not associated  with 
PCOS 
Bjercke S 
2002 
 29 NIR PCOS 
23 IR PCOS singleton pregnancies 
355 AR women 
PCOS: 13% PE  
(IR; 22%, and  NIR; 7%) 
AR-controls: 7% PE 
Higher incidence of PE in IR-PCOS 
compared to NIR-PCOS and controls 
Sir-Peterman T 
2002 
Prospective 20 PCOS 
26 Singleton controls  
PCOS:                        10% PE 
Controls:                      0% PE 
High rate of PE in PCOS 
Haakova L 
2003 
Retrospective 66 PCOS 
66 age and weight matched controls 
Singletons and multiple gestations mixed 
No difference between the 
groups 
PCOS not associated with high risk of PE 
LOD = Laparoscopic ovarian drilling   IR    = Insulin Resistant    PE     = Pre-eclampsia 
PIH   = Pregnancy Induced Hypertention   NIR = Non Insulin Resistant   AR   = Assisted Reproduction 
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Table 9.  PCOS and preterm delivery 
Name of first 
author and year 
of publication 
Study design Participants Results Conclusions 
 
 
Gjønnæss H 
1989 
Retrospective 
No controls 
69 PCOS after LOD Preterm:                   < 32 weeks: 10 % 
Perinalal mortality:   >16 weeks: 7.3% 
High prevalence of  preterm delivery. 
Mikola M  
2001 
Retrospective  
Singletons and twins 
80 PCOS women 
with 99 pregnancies 
737 controls 
PCOS:                         10% preterm 
Controls:                       6% preterm 
In singleton pregnancies 
No significant difference in preterm 
 
Jakubowicz DJ 
2002 
Retrospective 
 
18 PCOS no metformin 
62 PCOS + metformin  
 
PCOS no metformin:   33% preterm 
PCOS + metformin:     15% preterm 
 
High incidence of preterm delivery       
(< 37 weeks) in PCOS 
Bjercke S 
2002 
Retrospective? 29 NIR PCOS 
23 IR PCOS singleton 
355 AR women 
PCOS:                          23% preterm 
AR-controls:                15% preterm 
 
High incidence of preterm delivery (<37 
weeks) in PCOS women 
Haakova L 
2003 
Retrospective   
Singletons and twins 
66 PCOS 
66 age and weight 
matched controls 
Same gestational age in PCOS and 
controls if only singletons were 
studied 
No difference in length of gestation in 
singleton pregnancies 
Glueck CJ 
2004 
Prospective  
 
90 PCOS women  with 97 
pregnancies. Metformin 
treatment in pregnancy. 
252 Healthy controls 
PCOS:                          20% preterm 
Controls:                      10% preterm 
 
Increased risk for preterm delivery (<37 
weeks) in PCOS 
 
LOD  = Laparoscopic Ovarian Drilling 
AR     = Assisted Reproduction 
NIR = Non Insulin Resistant 
IR  = Insulin Resistant 
 Table 10.  Animal and in vitro studies on metformin effects in pregnancy 
 
Name of the first 
author and year of 
publication 
Study 
design 
Subjects Metformin dose and 
treatment period 
 
Results  Conclusions
Cohen Y 
1961 
Laboratory 
study 
Mouse  
Radio-labeled 
metformin 
Not available No visible radioactivity in the fetus 
after 1 and 4 hours. 
The placenta was radioactively 
marked 
Metformin passes to the 
placenta, but not to the fetus 
Tuchman-Duplessis H 
Mercier-Parot L  
1961 
Laboratory 
study 
Rat 500 – 1000 mg/kg 
(10-20 x human therapeutic 
dose) 
Less than 0.5 % major 
malformations 
Metformin is not teratogenic 
Denno KM 
1994 
Laboratory 
study 
In vitro 
Mouse embryo 
culture 
0.15-1.8 mg/ml metformin 
solution 
30 hours of culture 
No alterations of embryonic 
growth, no major malformations. 
Delayed closure of neural tube 
Metformin is not teratogenic 
 
Bedaiwy MA 
2001 
Laboratory 
study 
In vitro 
Two-cell mouse 
embryos  
5-100 µg/ml, 72 hours of 
culture 
Normal embryonic development at 
5 folds higher doses than the 
maximum clinical dose 
recommended for humans 
Metformin is not teratogenic. 
No direct toxic effect on mouse 
embryo development. 
 
62  
   
 Table 11.  Studies on diabetic women treated with metformin in pregnancy 
 
Name of first author 
and year of publication 
Study design Participants Metformin dose and 
treatment period 
 
Results  Conclusions
Cited in Stowers JM and 
Clark TM 
1975 
Analysis method: 
Pignard 1962 
Amniotic fluid  from two 
women 
850 mg daily and  
500 mg daily 
75µg/100 mL and 90µg/100 
mL metformin 
Metformin passes the placenta 
Stowers JM and 
Sutherland HW 
1975 
Retrospective  5 women with diabetes 1000 – 3000 mg daily 
Mean 40 days before 
delivery 
All babies survived Metformin is not teratogenic 
Pedersen J 
Mølstedt-Pedersen L 
1975 
Retrospective  15 women with GDM 1500 mg daily 
Entire pregnancy 
Mostly in III. trimester 
Perinatal mortality in the 
metformin treated group 
similar to the total diabetic 
population 
Metformin is not teratogenic 
No evidence of adverse effect of 
metformin in mother or child 
Coetzee EJ 
1979 
Retrospective  33 women with diabetes 
type-2 and GDM 
1500 – 3000 mg daily 
in the II. and III. 
trimester 
2 perinatal deaths  
(one malformation and one 
prematurity) 
Lower mortality and morbidity in the 
metformin treated group compared to no 
treatment or insulin treatment groups 
Coetzee EJ 
1984 
Retrospective 21 women with diabetes 
type-2 
1000 – 3000 mg daily 
in the I. trimester 
1 minor congenital 
abnormality 
Metformin is not teratogenic 
No difference in perinatal mortality and 
morbidity in diabetic women who 
received metformin during the firs 
trimester and those who did not 
Piacquadio K 
1991 
Observational One woman with 
diabetes type-2 
Dose unknown 
I.trimester 
Healthy baby Metformin is not teratogenic 
 
Hellmuth E 
1993 
Retrospective 7 women with  
diabetes type-2 
1000 - 2000 mg daily 
5-39 weeks treatment 
No congenital 
malformations 
Metformin is not teratogenic 
 
Sarlis NJ 
1998 
Case report One hyper-androgenic 
patient 
1000 mg daily 
From weeks 14 - 30 
Decreased maternal total 
testosterone level 
Metformin is not teratogenic 
No malformations or other adverse effects 
Hellmuth E 
 2000 
Retrospective  
Not randomized 
50 women with diabetes 
type-2 or GDM  
Compared with 42 
insulin treated women 
Accumulated dose: 1,5 
– 507 g. 
Gestational weeks  13-
40  
Metformin group: 31% PE 
                              12% PM  
Insulin group:        10% PE 
                              1.3% PM 
Prevalence of pre-eclampsia and perinatal 
mortality higher in the metformin group 
PE =  Pre-eclampsia 
PM =  Perinatal Mortality 
GDM =  Gestational Diabetes Mellitus 
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Table 12.  Studies on PCOS women according to metformin use in pregnancy 
 
Name of  first 
author and year of 
publicaion 
Study design Participants Metformin dose and 
treatment period 
 
Results  Conclusions
Jakubowicz DJ 
2002 
Retrospective  65 PCOS women
68 pregnancies   
 
32 PCOS women - no 
treatment 
1000 - 2000 mg daily 
Before conception and 
throughout pregnancy 
1 achondrodysplasia  
(inherited disorder) 
Metformin is not teratogenic 
Glüeck  CJ 
2004 
Prospective 
  
126 PCOS women 
151 pregnancies 
1500 – 2550 mg daily 
Before conception and 
throughout pregnancy 
1 sacrococcygeal teratoma 
1 tethered spinal cord 
Metformin is  not teratogenic.  
No negative effect on birth size or 
psychomotor development during the 
first 18 month of life 
 
  
Table 13.  Changes in maternal androgen levels in PCOS women during pregnancy, according to treatment by metformin or placebo. 
Measured by two different methods. 
 
  Inclusion Change to  
week 19 
Change to  
week 32 
Change to  
week 36 
   
Group N 
 
Mean (SD) 
 
N 
 
Mean (SD) 
 
N 
 
Mean (SD) 
 
N 
 
Mean (SD) 
 
        Elecsys Extraction 
+ RIA 2010 
Elecsys
2010 
Extraction 
+ RIA 
Elecsys
2010 
Extraction 
+ RIA 
Elecsys 
2010 
Extraction 
+ RIA 
              
Androstenedione (nmol/L) Placebo 21 23.4 (16.6) 18.2 (12.1) 21 -0.5 (16.6) -2.1 (12.5) 18 8.9 (27.5) 4.6 (20.2) 17 16.8 (28.5) 6.2 (17.5) 
 Metformin 17 20.0 (5.8) 14.3 (6.2) 17 1.6 (5.7) -1.9 (4.5) 17 3.7 (4.1) 1.0 (4.3) 17 13.1 (10.6) 5.2 (4.3) 
Testosterone  (nmol/L) Placebo 21 4.2 (2.6) 4.4 (2.9) 21 -1.0 (2.4) -0.1 (2.9) 18 -0.0 (5.1) 1.7 (6.7) 17 0.4 (5.0) 2.5 (6.9) 
 Metformin 17 3.7 (1.5) 3.5 (1.8) 17 - 0.8 (1.1) 0.3 (1.8) 17 -0.9 (1.1) 0.4 (1.8) 17 -0.3 (1.3) 1.6 (2.6) 
Free Testosterone Index  Placebo 21 4.3 (3.8) 4.0 (2.8) 21 -3.0 (3.4) -2.3 (2.3) 18 -3.2 (3.9) -2.2 (3.2) 17 -3.4 (3.9) -2.4 (2.9) 
 Metformin 3.7 (2.6) 
 
17 3.2 (2.2) 17 -2.7 (2.5) -1.8 (2.2) 17 -2.8 (2.4) -1.9 (2.0) 17 -2.7 (2.4) -1.7(2.1) 
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Metformin passes the placenta. Fetal serum levels are comparable with maternal values. (Fertil Steril 2005;
83:1575–8. ©2005 by American Society for Reproductive Medicine.)
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Ahe biguanide derivative metformin is an oral hypoglyce-
ic drug used in type 2 diabetes. It improves glucose
olerance mainly by decreasing hepatic glucose production
nd by increasing insulin sensitivity. Metformin is a highly
ater-soluble drug. It is not metabolized and is eliminated
hrough the kidneys by tubular secretion (1–3). The recog-
ition that metformin induces ovulation in many women
ith polycystic ovary syndrome (PCOS) (4, 5) has resulted
n more or less controlled use of metformin in the first
rimester, although it is not licensed for use in pregnancy.
Recent studies indicate that metformin might reduce
regnancy complications such as gestational diabetes and
remature delivery in women with PCOS (6–8). As the
ncidence of type 2 diabetes increases also in the younger
ge groups, metformin will probably be more extensively
sed in pregnant women in the future. The effect of met-
ormin on the fetus is essentially unknown. However, ter-
togenic effects have not been reported in humans (8–10).
ata on the passage of metformin across the placenta are
ew and contradictory. A study in rodents suggested no
lacental passage of metformin (11); in humans, placental
lucose uptake seems unaffected by metformin (12).
In a recent report, metformin was detected in umbilical
ord blood at delivery (13). However, in that small study,
rterial and venous umbilical cord blood were not analyzed
eparately and it is unclear whether the maternal venous
lood samples were obtained at delivery or earlier during
regnancy. Moreover, as the maternal venous and the cord
lood samples were not obtained at the same time interval
elative to the last dose intake of metformin, the study
esign is inappropriate to provide a precise quantitative
stimate of the transplacental passage of the drug.
The aim of our study was to investigate to what extent
etformin passes to the fetus in women with PCOS. Be-
ause metformin may induce lactic acidosis, we also inves-
igated if metformin affected the acid–base status of the
ewborn.
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here (8). In brief, 18 pregnant women with PCOS were
reated with metformin, 850 mg twice daily. The women
tarted treatment between gestational weeks 5 and 12 (on
verage, at gestational week 8) and continued the medica-
ion until delivery. One woman withdrew within 2 weeks
fter inclusion because of motivation failure. The remain-
ng 17 women completed the study. One woman gave birth
n an ambulance without any possibilities for blood sam-
ling, and blood samples from another one were missing
or administrative reasons. Thus, the results are presented
or a total of 15 women.
All participants received written and individual-verbal
iet and lifestyle counseling at their inclusion to the study
n early pregnancy. Thereafter, treatment with metformin
metformin, 425-mg capsules; Weifa AS, Oslo, Norway)
as initiated. All participants used 850 mg, once daily,
uring the first week and 850 mg, twice daily (1700 mg/
ay), for the rest of the study period. Three of the 15
omen used a reduced dosage (850 mg/day) because of
astrointestinal side effects. Written informed consent was
btained from each patient before inclusion in the study,
nd the declaration of Helsinki was followed throughout
he study. The Committee for Medical Research Ethics of
ealth Region IV, Norway, and The Norwegian Medicines
gency approved the study.
Blood samples from an antecubital vein of the mother
nd the umbilical artery and umbilical vein were separately
rawn within 1 hour after delivery. Blood samples were
entrifuged at room temperature within 30 minutes, and the
erum was stored (8 to 36 months) at70°C until analysis.
mmediately after delivery, the pH, base excess (BE), PO2,
nd PCO2 were measured in the umbilical artery blood using
Rapidlab 248pH/Blood Gas Analyzer (Bayer Corp., Tar-
ytown, NY) with reagents and calibrators supplied by the
anufacturer.
Metformin in serum was analyzed by a liquid chroma-
ography–mass spectrometry method. In brief, metformin
as precipitated from serum according to the procedure of
hang et al. (14) with the modifications of Chen et al. (15).
he mass spectrometric analysis was performed on an
gilent 1100 LC-MSD single quadrupole instrument (Agi-ent Technologies, Palo Alto, CA). Metformin and the
1575Fertility and Sterility Vol. 83, No. 5, May 2005
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TABLE 1
Metformin concentrations in maternal and umbilical cord blood in women with polycystic ovary syndrome treated with metformin
(850 mg, twice daily).
Patient
No.
Last drug
intake
before
sampling
(hours)
Maternal
serum
concentration
(mol/L)
Umbilical vein
serum
concentration
(mol/L)
Umbilical artery
serum
concentration
(mol/L)
pH in
umbilical
artery
blood
Base excess
in umbilical
artery blood
(mmol/L)
PO2 in
umbilical
artery blood
(kPa)
PCO2 in
umbilical
artery blood
(kPa)
APGAR score
at 1, 5, and
10 minutes
1 4 13.73 12.54 11.94 7.04 7.5 1.09 11.72 7, 7, 8
2 12 0.68 2.31 2.81 7.25 4.2 2.37 7.10 9, 9, 10
3 14 2.80 3.96 5.02 7.25 4.5 2.79 7.02 9, 9, 10
4 16 1.59 1.96 2.06 missing missing missing missing 9, 9, 10
5a 17 1.90 2.92 3.25 7.34 0.1 1.45 6.52 9, 10, 10
6 20 0.86 2.81 3.21 7.24 5.7 2.46 6.95 8, 10, 10
7 20 2.02 3.24 3.16 7.30 0.2 2.49 7.24 9, 10, 10
8a 32 0.08 0.21 0.26 7.33 3.2 2.94 5.89 9, 9, 10
9 unknown 3.60 5.92 6.47 7.26 8.7 3.61 5.54 9, 9, 10
10 unknown 6.29 5.30 4.76 missing missing missing missing 10, 10, 10
11 unknown 0.64 1.83 1.36 7.28 9.8 2.35 4.88 9, 10, 10
12 unknown 4.32 7.84 6.81 missing missing missing missing 4, 7, 8
13 unknown 0.05 1.25 1.55 7.27 missing missing missing 9, 10, 10
14 48 0.00b 0.00b 0.00b 7.28 0.3 0.63 8.03 9, 10, 10
15a 48 0.00b 0.00b 0.00b 7.27 13.7 3.93 3.56 9, 9, 10
Median 1.50 2.81 3.16 7.27 4.5 2.46 6.95
(IQR)e (0.50; 3.60) (1.25; 5.30)c (1.36; 5.02)d (7.25; 7.30) (8.7; 0.2) (1.45; 2.94) (5.54; 7.24)
a Metformin dose: 850 mg daily.
b Below the limit of detection of the method.
c Metformin concentration in umbilical vein versus matermal serum: P.017.
d Metformin concentration in umbilical artery versus matermal serum: P.033.
e Interquartile range.
Vanky. Placental passage of metformin in women with PCOS. Fertil Steril 2005.
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Fenternal standard diphenhydramine were monitored at m/z
30.1 and 256.2, respectively, using electrospray positive
onization. Unknown samples were analyzed together with
uality control samples and calibrators covering a range
rom 0.05 (limit of detection) to 50 mol/L.
All statistical procedures were performed using the SPSS
ersion 11.0 for Windows (SPSS Inc., Chicago, IL). For
omparative statistics, Wilcoxon’s test and Spearman’s
ank correlation test were used, as the data were not nor-
ally distributed. Consequently, data are presented as me-
ians and interquartile ranges. P.05 was considered sta-
istically significant.
Metformin concentrations were detectable in 13 of the
5 maternal serum samples, ranging from 13.78 mol/L 4
ours after drug intake, to 0.08 mol/L 32 hours after last
rug intake. Except for two patients (patients 1 and 10),
etformin was detected in both umbilical vein and umbil-
cal artery in higher concentrations than in maternal serum
Table 1). Metformin concentrations in both the umbilical
ein (P.017) and the artery (P.033) were higher than
etformin levels in maternal venous blood. Maternal met-
ormin concentrations were significantly correlated to met-
ormin levels in the umbilical vein (R20.96, P.001) and
mbilical artery (R20.90, P.001). Concentrations in the
mbilical artery and umbilical vein were close to equal (see
able 1). The pH, BE, PO2, and PCO2 in umbilical artery
lood did not statistically significantly correlate to the
etformin concentration in maternal serum or umbilical
rtery or umbilical vein serum.
The present finding, that a significant amount of met-
ormin passes to the fetus, supports the results of Hague et
l. (13). However, contrary to that study, we found that the
etformin concentrations in both umbilical artery and vein
erum were roughly the same as in maternal serum. The
eason for the discrepancy between these studies is that in
he study by Hague et al. (13) the maternal venous blood
amples were obtained 4.5 hours after the intake of the last
etformin dose whereas umbilical cord blood was obtained
0 hours after intake of the last metformin dose. In contrast,
n our study, all blood samples were obtained simulta-
eously. Given the short elimination half-life of metformin
1.5 to 4.5 hours), a delay in umbilical blood sampling
elative to maternal venous blood sampling will errone-
usly underestimate the transplacental passage of met-
ormin.
Our results indicate that metformin passes freely through
he placenta and that the fetus is exposed to levels of
etformin comparable with therapeutic concentrations in
dults. Our findings also indicate that, except for the first
ours after metformin intake, the fetus is exposed to higher
oncentrations of metformin than the mother. The knowl-
dge on metformin metabolism in the fetus is scarce. In
dults, metformin is eliminated by renal tubular secretion.
ence, one may speculate that in the fetus some of the
rtility and Sterilityetformin is excreted to the amniotic fluid (16) and reab-
orbed to the fetal circulation by swallowing. Metformin is
hen eliminated from the fetus by passage through the
lacenta into the maternal circulation.
This would explain our findings of higher fetal met-
ormin concentrations in all but two fetuses as compared
ith the maternal levels. The two latter cases represent the
wo mothers with the highest metformin concentrations,
ost likely due to a short time interval from metformin
ntake. The fact that the fetus seems to be exposed to higher
oncentrations than the mother for a substantial part of a
ose interval is noteworthy. It indicates that longitudinal
tudies on the effect of metformin exposure in pregnancy
hould be conducted in the offspring into adult age. Also,
he incidence of metabolic syndrome should be investi-
ated in these individuals.
In conclusion, the results from the present study indicate
hat metformin freely passes the placenta and that the
etuses are exposed to therapeutic concentrations. Although
o teratogenic effects are reported for metformin, and
etformin does not seem to influence pH levels in umbil-
cal artery blood, we nevertheless consider long-term
ollow-up to be mandatory in these infants.
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Capsule: 
The preventive effect of metformin on pregnancy complications in PCOS women seems not 
to be associated with major changes of CRP levels or indices of coagulation factors and 
fibrinolysis.  
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Abstract 
Objective: To investigate a possible effect of metformin on C-reactive protein levels and 
indices of coagulation factors and fibrinolysis in pregnant women with polycystic ovary 
syndrome. 
Design: Randomised double blind placebo-controlled study.  
Setting: University hospital. 
Patient(s): Forty pregnant women with polycystic ovary syndrome followed through 
pregnancy.  
Intervention(s):  All patients received diet and lifestyle counselling and were randomised to 
either metformin 850 mg twice daily or placebo. Outcome measures were serum levels of C-
reactive protein and indices of coagulation factors and fibrinolysis.  
Result(s): In women with polycystic ovary syndrome, C-reactive protein levels as well as D-
dimer, antithrombin III, activated protein C resistance and activated partial thromboplastin 
time were unaffected by metformin treatment throughout pregnancy. Protein C levels 
increased slightly in the metformin group compared to the placebo group. 
 
Conclusions: Metformin treatment of pregnant women with polycystic ovary syndrome 
seems to prevent pregnancy complications but this effect is unlikely to be associated with 
major changes of CRP levels or indices of coagulation or fibrinolysis.  
 
Key words: coagulation factors / C-reactive protein / metformin / PCOS  
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Women with polycystic ovary syndrome (PCOS) have increased risk for spontaneous 
abortion (1-6) and pregnancy complications, such as gestational diabetes mellitus  (7-10), 
preterm delivery (3;9;11;12) and preeclampsia (11;13;14). Recently, we reported that 
metformin treatment throughout pregnancy prevented pregnancy complications in PCOS 
women. However, the preventive effect of metformin was not explained by changes in 
androgen levels as we hypothesized (4).  
Polycystic ovary syndrome (PCOS) has been associated with an increased risk for 
cardiovascular disease (15-17) and a 3 fold increased risk of postmenopausal hypertension 
(18). As many as forty percent of women with PCOS may have impaired glucose tolerance or 
type 2 diabetes (19;20). C-reactive protein (CRP) is a sensitive indicator of systemic 
inflammation (21). Studies show that chronic low-grade inflammation, as measured by CRP, 
is strongly predictive for the development of cardiovascular disease and type-2 diabetes  (22-
26). Several studies demonstrate elevated CRP levels in PCOS women compared to healthy 
controls (27-30), although also one negative study has been published (31).  
Morin-Papunen found that metformin reduced CRP levels in non-pregnant PCOS women 
(32). 
First trimester CRP levels are increased among women who subsequently develop 
gestational diabetes mellitus, preeclampsia and fetal growth restriction (33-37). The effect of 
metformin on CRP levels in pregnant PCOS women has not been reported. 
PCOS women have impaired fibrinolytic capacity, which may partially explain an 
increased risk for deep venous thrombosis (38). Thrombosis of the placenta is sometimes the 
cause of placental insufficiency and fetal demise (39). Velazquez et al. found that  metformin 
treatment reduced plasminogen activator inhibitor-1 (PAI-1) in non-pregnant women with 
 
 6
PCOS (40). Thus, a possible effect of metformin on indices of coagulation or fibrinolysis 
could help to explain the preventive effect of metformin against pregnancy complications. 
  We hypothesized that metformin could influence CRP levels and /or indices of 
coagulation and fibrinolysis. Serum from a previously reported prospective randomized trial 
was used to investigate if coagulation and fibrinolysis indices could hint possible mechanisms 
of action of metformin in PCOS pregnancies (4).  
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MATERIALS AND METHODS 
From October 2000 to March 2003, 40 pregnant women with PCOS were recruited from the 
gynaecological and the infertility outpatient clinic at The University Hospital of Trondheim. 
The women were included in a prospective, randomised, placebo controlled trial with the aim 
to study the effect of metformin treatment on androgen levels and pregnancy complications 
PCOS women (4). Inclusion criteria in the trial were: 1) diagnosis of PCOS before the actual 
pregnancy, 2) age 18 to 40 years, 3) gestational age between five and twelve weeks, and 4) a 
singleton viable fetus judged by ultrasonography. The diagnosis of PCOS was based on the 
presence of polycystic ovaries (nine or more sub-capsular follicles with a diameter of 3-8 
mm) verified by transvaginal ultrasonography. Furthermore, at least one of the following five 
criteria had to be present: testosterone > 2.5 nmol/l, sex hormone binding globulin (SHBG) < 
30 nmol/l, fasting insulin C-peptide > 1.0 nmol/l, oligo-amenorrhea (length of menstrual 
cycle > 35 days or less than ten periods per year), or hirsutism (judged clinically as male 
pattern growth of body hair). The study population have been described in detail previously 
(4). All women in the study fulfilled the “Revised 2003 consensus” on diagnostic criteria for 
PCOS (41).  
All participants signed a written informed consent before inclusion. The Regional 
Committee for Medical Research Ethics and The Norwegian Medicines Agency approved the 
study. The declaration of Helsinki was followed throughout the study. 
At the time of inclusion (≤ gestational week 12) and later at gestational weeks 19, 32 
and 36, venous blood samples were drawn from an antecubital vein, between 8:00 and 11:00 
a.m. after an overnight fast. Blood samples for CRP analysis, were centrifuged at room 
temperature within 30 minutes and stored at –70oC until analysis (6-28 months). Coagulation 
factors were analysed subsequently on the day of sampling. 
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Study protocol 
All participants received individual, verbal and written diet and lifestyle counselling at 
inclusion. Eighteen women were randomised to metformin medication and twenty-two to 
placebo. Randomisation was performed in blocks of ten and women were stratified according 
to whether or not they used metformin at conception.  
At conception eleven women in the placebo group and eight in the metformin group used 
metformin. Seven of the women who used metformin at conception (five in the placebo group 
and two in the metformin group), continued to use it until a few days before inclusion. All 
women had a “wash out” period of at least two days before inclusion. The randomised groups 
were balanced with respect to maternal age, body mass index (BMI), and gestational age at 
the time of inclusion, apart from diastolic blood pressure which was higher in the metformin 
group(4). 
The women in the study group received two capsules of metformin 425 mg (metformin 
hydrochloride, Metformin®, Weifa AS, Oslo, Norway) twice daily, and the control group 
received identical placebo capsules. All participants used two capsules once daily during the 
first week and two capsules twice daily for the rest of the study period. In addition, they all 
received 1 mg of folate daily, and one daily multivitamin tablet. Two women, one in each 
group, withdrew within two weeks after inclusion. The remaining 38 women completed the 
study.  
Assays  
CRP was analysed on a Roche/Hitachi 902 analyzer using a Tina-quant CRP high sensitive 
assay (Mannheim, Germany). D-dimer and antithrombin III were analysed on a Hitachi 917 
instrument by the Tina-quant (Roche Diagnostics) and Coamatic 400 reagents (Chromogenics 
AB, Mölndal, Sweden), respectively. Activated partial thromboplastin time (APTT), activated 
protein C resistance (APC resistance) and protein C were analysed on a Trombolyzer 
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instrument from Behnk Elektronik using reagents from Nycomed Pharma AS (Oslo, Norway), 
Coatest APC-resistance V-S reagents (Chromogenics) and Coamatic Protein C reagents 
(Chromogenics), respectively. Protein S was analysed by enzyme-linked immunosorbent 
assay (ELISA) method with Coaliza reagents (Chromogenics).  
Statistical Analysis 
All statistical procedures were performed using the SPSS version 11.0 for Windows (SPSS 
Inc., Chicago, Illinois, USA). Values are reported as medians and inter quartile ranges (IQR). 
To evaluate the difference between the study groups, we used general linear model for 
repeated measures on log transformed values to overcome the effect of uneven distribution. 
For patient characteristics mean values and standard deviations are given and two-tailed T-test 
for independent samples were used. For correlation analyses we used Spaerman´s rho.
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RESULTS 
 
At inclusion, the placebo group and metformin group were equal regarding age (28.3 ± 3.7 
years vs. 28.9 ± 4.8 years, p = 0.7), BMI (29,3 ± 8.0 kg/m2 vs. 32.1 ± 6.1 kg/m2, p = 0.2), 
gestational age (55 ± 17 days vs. 59 ± 14 days, p = 0.4), and systolic blood pressure (117 ± 16 
mmHg vs. 120 ± 14 mmHg, p = 0.5). However, diastolic blood pressure was lower in the placebo 
group (72 ± 10 mmHg vs. 78 ± 9 mmHg, p = 0.05). At conception 50% of the women in the 
placebo group and 44% in the metformin group used metformin (p = 0.8).  
At inclusion, and throughout the study, CRP levels were equal in the two groups 
(Table 1). General linear model for repeated measures of CRP through pregnancy did not 
show tendency to differences between the groups (p = 0.51). CRP correlated to BMI at 
inclusion (R2 = 0.41; p < 0.001), at gestational week 19 (R2 = 0.36; p = 0.001), at gestational 
week 32 (R2 = 0.22; p = 0.005) and at gestational week 36 (R2 = 0.15; p = 0.02). 
Compared to the placebo group, protein C increased slightly in the metformin group (p 
= 0.04).  Metformin did not affect other measured coagulation and fibrinolytic factors during 
pregnancy.  
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DISCUSSION 
In a previous report, from the same study population we, reported that metformin reduced 
pregnancy complications among PCOS women, while androgens, SHBG and body mass 
index were unaffected through pregnancy (4). The present study is of limited size, but it is 
performed on a well-characterized population in a prospective, controlled design. To our best 
knowledge this is the first study to report on CRP levels and coagulation parameters through 
pregnancy in metformin treated PCOS patients. 
CRP is a surrogate marker for inflammation and is associated with poor outcome in 
both cardiovascular diseases and a variety of obstetric conditions (24;25;33;37;42;43). 
Furthermore, CRP is elevated in PCOS and other aspects of the metabolic syndrome (27-29). 
We therefore hypothesized that metformin might reduce CRP levels in pregnant PCOS 
women, but we found no such effect in the present study. This is surprising since Morin-
Papunen found that metformin decreased CRP levels in non-pregnant PCOS women (32). 
Metformin treatment in that study was however compared to ethinyl estradiol (35 µg) 
cyproterone acetate (2 mg) and not placebo, and the study participants were not pregnant. In 
PCOS women elevated CRP levels associated with adiposity, and weight loss resulted in 
reduced CRP in non-pregnant PCOS women (32). Thus, one possible explanation for the lack 
of association between CRP levels and metformin in the present study might be that 
metformin influence pregnant and non-pregnant women differently. There is also a possibility 
for type 2 statistical errors in studies with small numbers of participants. However, the present 
study indicates that prevention of pregnancy complications in PCOS women by metformin is 
not mediated by a major effect on inflammation, as measured by CRP.  
 Decreased fibrinolysis has been observed in non-pregnant PCOS women (38). In the 
present study, we observed an effect of metformin on protein C. Increased Protein C levels 
would, at least theoretically, indicate a positive effect of metformin on coagulation. We do, 
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however, not think that this is an important factor in the action of metformin, since the size of 
the difference is relatively small and protein C levels were within the normal range in the both 
groups.  
We also studied thrombophilic factors and in keeping with the study by Tsanadis we 
found no increased incidence of thrombophilia (44). This is in contrast to a study by 
Velazquez among non-pregnant women with PCOS (45). She found an effect of metformin 
treatment on fibrinolysis measured by PAI-1, indicating that metformin increases fibrinolysis. 
More sensitive assessments of fibrinolytic capacity were not performed in our study. 
Measurements of D-dimer are however, sensitive enough to detect improved fibrinolysis in 
non-pregnant PCOS women on low-calorie diet (46).  
There is an increasing body of evidence that metformin may have a preventive effect 
on pregnancy complications. Its possible mechanism of action is, however, still not 
understood. Neither inflammation, as measured by CRP, nor disturbances in coagulation or 
fibrinolysis seem to explain the beneficial effect of metformin. Other, still unveiled, 
mechanisms are probably involved. Well-designed, large-scale studies are needed both to 
confirm the positive effect of metformin on pregnancy complications and to clarify the 
mechanisms that might be involved.  
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Table 1. CRP and indices of coagulation factors and fibrinolysis in pregnant PCOS women according to treatment group. 
 
     
Inclusion 
 
Week 19 Week 32 
 
Week 36 
      Group N  Median IQR N Median IQR   MedianN  IQR N Median IQR P- a 
value 
                 
CRP mg/L Placebo 21 5.7 2.4 – 9.4 
 
21 7.6 3.4 – 12.3   18 5.8 1.8 – 10.0 17 7.4 2.6 – 9.1  
 Metformin 16 4.1 1.1 – 10.2 16 7.2 2.9 – 17.0   16 5.4 2.2 – 14.1 16 4.3 2.1 – 7.6 0.51 
APTT (seconds) Placebo 
 
19 25 23 - 27 18 25 24 - 27   15 26 24 - 26 15 25 23 - 26  
 Metformin 17 25 23 - 28 16 25 23 - 28   16 24 22 - 27 15 25 23 - 26 0.88 
D-dimer (mg/L) Placebo 
 
20 0.30 0.22 – 0.48 19 0.40 0.40 – 0.70   16 0.80 0.60 – 1.00 16 1.05 0.70 – 1.40  
 Metformin 17 0.20 0.20 -  0.30 16 0.40 0.30 – 0.50   16 0.60 0.45 – 1.00 15 0.95 0.55 – 1.38 0.12 
Antitrombine III 
(%) 
Placebo 20 102 90 - 112 19 98 90 - 106   15 106 94 - 111 16 102 99 - 110  
 Metformin 17 102 89 - 108 16 104 90 - 107   16 105 100 - 114 15 104 999 - 112 0.48 
APC resistance Placebo 20 1.01 0.97 -  1.06 19 0.98 0.94 – 1.01   16 0.98 0.92 – 1.03 16 1.00 0.90 – 1.05  
 Metformin 17 1. 03 1.00 – 1.04 16 1.01 0.97 – 1.09   15 1.00 0.97 – 1.04 15 0.99 0.95 – 1.03 0.16 
Protein C (%) Placebo 22 106 96 - 117 20 117 98 - 130   17 106 99 - 121 17 102  86 - 116  
 Metformin 18 108 102 – 130 
 
16 128 108 - 130   17 117 104 - 130 15 124 102 - 130 0.04 
Protein S (%) Placebo 22 76 50 - 96 20 61 55 - 71   17 45 44 - 56 16 46 39 - 52  
 Metformin 17 87 65 - 112 14 60 56 - 72   16 53 44 - 66 14 53 48 - 56 0.28 
 
a   p value for general linear model for repeated measures on log transformed values 
 
